Clinical Trials - BMY

NCT IDTitleStatusPhasesStart DateCompletion DatePrimary Completion Date
NCT07171983A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid ArthritisNOT_YET_RECRUITINGPHASE12026-01-222027-08-252027-06-28
NCT07195682A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)NOT_YET_RECRUITINGPHASE12025-12-152031-04-032030-05-03
NCT06937229A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)NOT_YET_RECRUITINGPHASE32025-11-212029-07-202029-06-22
NCT07076121A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)RECRUITINGPHASE2, PHASE32025-11-032029-05-032029-05-03
NCT07015242A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System LymphomaNOT_YET_RECRUITINGPHASE22025-10-312028-12-102028-01-09
NCT07160725A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid TumorsNOT_YET_RECRUITINGPHASE1, PHASE22025-10-282028-08-012028-07-31
NCT07106762Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After ImmunotherapyNOT_YET_RECRUITINGPHASE2, PHASE32025-10-222033-11-182029-01-26
NCT07077434A Study to Assess Safety, Tolerability and Drug Levels of BMS-986504 in Participants With Advanced Solid TumorsNOT_YET_RECRUITINGPHASE12025-10-222027-01-192027-01-19
NCT07100080Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)NOT_YET_RECRUITINGPHASE2, PHASE32025-10-152031-05-152028-09-15
NCT07063745A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP DeletionRECRUITINGPHASE2, PHASE32025-10-062031-08-122031-08-12
NCT06979453A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque PsoriasisRECRUITINGPHASE32025-09-252034-08-122029-10-12
NCT07116967Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)RECRUITINGPHASE32025-09-222031-01-162031-01-16
NCT06181630A Lactation Study in Women Receiving Treatment With OzanimodRECRUITINGPHASE42025-09-162026-12-162026-12-16
NCT06946797A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)RECRUITINGPHASE22025-09-152028-10-252027-02-05
NCT06926868A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)RECRUITINGPHASE2, PHASE32025-09-112030-05-152028-03-13
NCT06855771A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)RECRUITINGPHASE22025-09-092031-12-302028-12-29
NCT07140913A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or LamotrigineNOT_YET_RECRUITINGPHASE32025-09-052027-06-282027-06-28
NCT07115745A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune DiseasesRECRUITINGPHASE12025-09-042030-08-162029-02-13
NCT07004972A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)RECRUITINGPHASE42025-09-042027-12-132027-12-13
NCT07061288A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With SchizophreniaRECRUITINGPHASE12025-09-032027-10-152027-06-21
NCT06875960A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132RECRUITINGPHASE42025-08-292026-12-012026-12-01
NCT06997029A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid TumorsRECRUITINGPHASE12025-08-012028-12-142028-12-14
NCT06947941A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)NOT_YET_RECRUITINGPHASE32025-07-312027-10-252027-09-27
NCT06976203A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)RECRUITINGPHASE32025-07-212029-02-232028-09-11
NCT06929273A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)RECRUITINGPHASE32025-07-182028-06-132028-06-13
NCT07011745A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)RECRUITINGPHASE32025-07-162028-11-132028-11-03
NCT07015983A Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)RECRUITINGPHASE22025-07-142032-06-152028-05-17
NCT06976216A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseaseRECRUITINGPHASE32025-07-142029-02-232028-09-11
NCT07011732A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)RECRUITINGPHASE32025-07-102028-12-082028-11-24
NCT07063342A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, and to Explore the Effect of Food After Multiple Doses of Selected Prototypes in Healthy Adult ParticipantsRECRUITINGPHASE12025-06-272026-02-282026-02-28
NCT06951711A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)RECRUITINGPHASE32025-06-132026-11-022026-11-02
NCT06951698A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I DisorderRECRUITINGPHASE32025-06-112026-11-012026-11-01
NCT06882785A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With SchizophreniaRECRUITINGPHASE32025-06-102029-08-232028-09-23
NCT06799286A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung CancerACTIVE_NOT_RECRUITINGPHASE12025-05-072027-05-262027-05-26
NCT06955741A Study to Assess Drug Levels, Tolerability and Absolute Biological Availability of Single-dose of BMS-986446 in Healthy ParticipantsCOMPLETEDPHASE12025-05-052025-09-112025-09-11
NCT06853171Safety, Tolerability, and Pharmacokinetics of KarXT and Dual-burst Release of Xanomeline With Immediate-release Trospium Chloride in Adolescents With Psychiatric DisordersCOMPLETEDPHASE12025-04-292025-07-222025-07-22
NCT06764771A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant TumorsRECRUITINGPHASE12025-03-252027-10-152027-10-15
NCT06672523A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase DeletionRECRUITINGPHASE12025-03-242026-04-202026-04-20
NCT06877702A Single-dose Study to Evaluate the Safety, Tolerability, Drug Levels, and Relative Biological Availability of Alternate Formulations of BMS-986460 in Healthy Adult Male ParticipantsRECRUITINGPHASE12025-03-192025-10-292025-10-29
NCT06869551A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic ArthritisRECRUITINGPHASE32025-03-132031-03-042030-03-06
NCT06615479A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)RECRUITINGPHASE32025-03-122032-06-222027-12-30
NCT06846866A Study to Investigate the Safety, Tolerability, and Drug Levels of BMS-986419 (Part 1) and the Effects Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy ParticipantsRECRUITINGPHASE12025-02-272025-10-222025-10-22
NCT06646276A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).RECRUITINGPHASE32025-02-252031-09-052028-04-06
NCT06697197A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid TumorsRECRUITINGPHASE1, PHASE22025-02-172029-01-052029-01-04
NCT06730750A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid TumorsRECRUITINGPHASE1, PHASE22025-02-122029-12-092026-09-05
NCT06746402A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy ParticipantsCOMPLETEDPHASE12025-02-102025-09-112025-09-11
NCT06618287A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid TumorsRECRUITINGPHASE1, PHASE22025-02-042028-08-242026-12-16
NCT06851871A Study to Evaluate the Bioequivalence Between Immediate Release Tablets and Minitablets of Deucravacitinib (BMS-986165), and the Effect of Food and pH on the Drug Levels of the Minitablets in Healthy AdultsCOMPLETEDPHASE12025-01-232025-04-042025-04-04
NCT06715683A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy ParticipantsCOMPLETEDPHASE12024-12-122025-03-162025-03-16
NCT06723535A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent HemodialysisRECRUITINGPHASE12024-12-072025-10-172025-10-17
NCT06544655A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid TumorsRECRUITINGPHASE12024-10-102027-10-142027-10-14
NCT06561386A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%RECRUITINGPHASE32024-10-072032-08-042030-07-30
NCT06566768Study to Evaluate Drug Levels of Various Solid Gastro-retentive Formulations of Deucravacitinib (BMS-986165) in Healthy ParticipantsCOMPLETEDPHASE12024-10-072025-06-132025-06-13
NCT06568458A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy ParticipantsCOMPLETEDPHASE12024-09-192025-02-272025-02-27
NCT06476808A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.RECRUITINGPHASE12024-09-062028-12-192028-12-19
NCT06577259Study to Assess Relative Bioavailability of BMS-986435 Formulations in Healthy Adult ParticipantsCOMPLETEDPHASE12024-09-032025-02-192025-02-19
NCT06493409A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy ParticipantsCOMPLETEDPHASE12024-08-262024-12-072024-12-07
NCT06481306A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell DiseaseRECRUITINGPHASE1, PHASE22024-07-172027-11-162027-01-06
NCT05209295A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid MalignanciesACTIVE_NOT_RECRUITINGPHASE12024-07-122025-06-302025-06-30
NCT06476821A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of Single Doses of BMS-986435 (MYK-224) in Healthy Chinese ParticipantsCOMPLETEDPHASE12024-06-272024-10-112024-10-11
NCT06476834A Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female ParticipantsCOMPLETEDPHASE42024-06-242024-11-022024-11-02
NCT06425198Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic ImpairmentCOMPLETEDPHASE12024-06-102024-12-302024-12-30
NCT06419634Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeRECRUITINGPHASE12024-05-292030-09-162027-02-01
NCT06396039A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple SclerosisACTIVE_NOT_RECRUITINGPHASE42024-05-152029-03-302028-12-29
NCT06352528A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic ImpairmentCOMPLETEDPHASE12024-04-292025-09-162025-09-16
NCT06253221A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic CardiomyopathyACTIVE_NOT_RECRUITINGPHASE32024-04-172031-03-282028-02-15
NCT06313996A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular LymphomaNOT_YET_RECRUITINGPHASE32024-03-292031-10-162031-10-16
NCT06220201A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)RECRUITINGPHASE12024-03-282027-07-152027-07-15
NCT06297226Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple MyelomaRECRUITINGPHASE22024-03-212032-06-302027-06-30
NCT06268886Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's DiseaseACTIVE_NOT_RECRUITINGPHASE22024-03-202027-03-182027-03-18
NCT06248814A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Participants With Atopic DermatitisACTIVE_NOT_RECRUITINGPHASE12024-03-062025-10-312025-10-31
NCT06121843A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple MyelomaRECRUITINGPHASE12024-02-222028-08-012028-08-01
NCT06144697A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy ParticipantsTERMINATEDPHASE12024-01-292024-10-162024-10-16
NCT06112743A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic CardiomyopathyACTIVE_NOT_RECRUITINGPHASE42024-01-242026-07-092026-07-09
NCT06153251A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple MyelomaRECRUITINGPHASE12024-01-232030-05-022030-05-02
NCT06205290A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i TherapiesWITHDRAWNPHASE32024-01-162031-10-132031-10-13
NCT06211179A Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to Intact Oral 5 mg Mavacamten in Healthy ParticipantsCOMPLETEDPHASE12024-01-102024-06-132024-06-13
NCT06090539A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin LymphomasRECRUITINGPHASE1, PHASE22023-12-292028-10-282027-10-28
NCT06140836A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)ACTIVE_NOT_RECRUITINGPHASE32023-12-212027-06-032027-03-13
NCT05838781DeteCtiON and Stroke PreventIon by MoDEl ScRreenING for Atrial FibrillationCOMPLETEDNA2023-12-042024-05-162024-05-16
NCT06094296A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)TERMINATEDPHASE22023-11-272024-08-082024-08-08
NCT06035497A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)RECRUITINGPHASE1, PHASE22023-11-202030-10-102027-01-30
NCT06086886A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986454 in Healthy ParticipantsCOMPLETEDPHASE12023-11-162024-12-202024-12-20
NCT06024174A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid TumorsTERMINATEDPHASE1, PHASE22023-11-092024-05-132024-05-13
NCT06122779Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)RECRUITINGPHASE22023-11-072026-07-032026-07-03
NCT06101134A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose CombinationsACTIVE_NOT_RECRUITINGPHASE22023-11-062027-08-312025-04-10
NCT06088264A Study to Evaluate the Drug Levels, Metabolism, and Removal of BMS-986322 in Healthy Adult Male ParticipantsCOMPLETEDPHASE12023-10-312023-12-222023-12-22
NCT06025578A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary FibrosisRECRUITINGPHASE32023-10-252027-12-272027-12-27
NCT05949684ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood TransfusionsRECRUITINGPHASE32023-10-242030-03-112027-06-25
NCT06067841A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate CancerACTIVE_NOT_RECRUITINGPHASE12023-10-182031-07-272029-08-24
NCT06084598A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986446 in Healthy Participants and Healthy Participants of Japanese EthnicityCOMPLETEDPHASE12023-10-122024-03-082024-03-08
NCT06042920A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital PsoriasisTERMINATEDPHASE42023-10-092025-04-252025-04-25
NCT06045689A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome ParticipantsACTIVE_NOT_RECRUITINGPHASE32023-10-052027-12-302026-01-01
NCT06034899A Study to Evaluate the Effect of Food on the Drug Levels of BMS-986196 in Healthy Adult ParticipantsWITHDRAWNPHASE12023-09-222023-11-302023-11-30
NCT06013995A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of LupusRECRUITINGPHASE12023-09-212026-04-122026-04-12
NCT06003426A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary FibrosisACTIVE_NOT_RECRUITINGPHASE32023-09-142026-10-262026-10-26
NCT05869955A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)RECRUITINGPHASE12023-09-132028-08-292028-08-29
NCT05946941A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's SyndromeRECRUITINGPHASE32023-09-112028-11-162026-11-18
NCT06027437A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult ParticipantsCOMPLETEDPHASE12023-09-052023-11-102023-11-10
NCT05470985A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional TherapyTERMINATEDPHASE2, PHASE32023-08-222024-09-132024-09-13
NCT05981976A Study to Evaluate the Drug Levels of Abatacept Converted From Drug Substance by Two Different Processes in Healthy ParticipantsCOMPLETEDPHASE12023-08-182023-12-142023-12-14
NCT05985590A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female ParticipantsCOMPLETEDPHASE12023-08-182023-12-112023-12-11
NCT05952089A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart FailureCOMPLETEDPHASE12023-08-172024-03-192024-03-15
NCT05981963A Study to Evaluate the Drug Levels, Physical and Chemical Changes, and Removal of BMS-986196 in Healthy Male ParticipantsCOMPLETEDPHASE12023-08-172023-10-222023-10-22
NCT05963932A Study to Assess the Bioavailability and Effect of Food of BMS-986419 Immediate-release Tablet Formulation in Healthy Adult ParticipantsCOMPLETEDPHASE12023-08-082023-10-172023-10-17
NCT05932303A Study to Assess the Effect of Multiple Doses of Itraconazole, Gemfibrozil, or Carbamazepine on BMS-986278 in Healthy ParticipantsCOMPLETEDPHASE12023-07-122023-10-232023-10-23
NCT05866627A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy ParticipantsRECRUITINGPHASE12023-07-042026-03-012026-03-01
NCT05932277A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy ParticipantsCOMPLETEDPHASE12023-06-292023-09-132023-09-13
NCT05827016A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple MyelomaRECRUITINGPHASE32023-06-222036-01-012029-03-15
NCT05901714A Study to Assess the Effect of Phenytoin on the Drug Levels of Afimetoran and the Effect of Afimetoran on the Drug Levels of MidazolamCOMPLETEDPHASE12023-06-142024-04-112024-04-11
NCT05888831A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid TumorsACTIVE_NOT_RECRUITINGPHASE1, PHASE22023-06-062026-09-302026-09-30
NCT05891262A Study to Evaluate the Drug-drug Interaction of BMS-986196 With Oral Contraceptives in Healthy Female ParticipantsCOMPLETEDPHASE12023-06-062023-08-252023-08-25
NCT05891249A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in IndiaACTIVE_NOT_RECRUITINGPHASE42023-06-052026-04-162026-04-16
NCT05852769A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy ParticipantsCOMPLETEDPHASE12023-05-312023-08-242023-08-24
NCT05496192A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder CancerWITHDRAWNPHASE22023-05-312026-06-242024-06-24
NCT05899738A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult ParticipantsCOMPLETEDPHASE12023-05-182023-07-062023-07-06
NCT05847439A Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]BMS-986419 in Healthy Male ParticipantsCOMPLETEDPHASE12023-05-052023-07-052023-07-05
NCT05688475A Rollover Study of CC-122ACTIVE_NOT_RECRUITINGPHASE12023-04-112026-02-252026-02-25
NCT05813717A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986325 in Healthy Japanese ParticipantsCOMPLETEDPHASE12023-04-102023-10-022023-10-02
NCT05730725A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe PsoriasisCOMPLETEDPHASE22023-04-032024-08-062024-08-06
NCT05806359A Study to Evaluate the Safety, Tolerability, and Drug Levels of Danicamtiv in Healthy Japanese and Caucasian ParticipantsCOMPLETEDPHASE12023-03-312023-08-142023-08-14
NCT05805904A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986278 in Healthy Chinese ParticipantsCOMPLETEDPHASE12023-03-292023-05-232023-05-23
NCT05760937A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986447 in Healthy ParticipantsCOMPLETEDPHASE12023-03-102023-11-272023-11-27
NCT05625399A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable MelanomaACTIVE_NOT_RECRUITINGPHASE32023-03-062027-11-182025-08-04
NCT05707390A Study of Mezigdomide in Healthy Participants and Participants With Hepatic ImpairmentCOMPLETEDPHASE12023-02-202023-09-132023-09-13
NCT05719805A Study to Evaluate the Effects of Mavacamten in Healthy ParticipantsCOMPLETEDPHASE12023-02-202023-07-252023-07-25
NCT05638282A Study to Evaluate the Safety and Tolerability of Cendakimab in Chinese Healthy ParticipantsCOMPLETEDPHASE12023-02-152023-06-272023-06-27
NCT05613088A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube CancerACTIVE_NOT_RECRUITINGPHASE22023-02-012026-10-112024-06-17
NCT05701995A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community SettingCOMPLETEDPHASE42023-01-312025-05-292024-08-23
NCT05556343A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic CardiomyopathyTERMINATEDPHASE22023-01-182025-02-272024-08-19
NCT05686096A Study to Evaluate the Absorption, Metabolism, and Excretion (ADME) of BMS-986435COMPLETEDPHASE12023-01-162023-04-082023-04-08
NCT05617677A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)RECRUITINGPHASE32023-01-122027-12-172025-12-17
NCT05620407A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus ErythematosusRECRUITINGPHASE32023-01-122027-12-172025-12-17
NCT05552976A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)RECRUITINGPHASE32023-01-102029-07-252026-02-04
NCT05678283A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid TumorsWITHDRAWNPHASE12023-01-092024-04-292024-04-29
NCT05658146A Study to Assess the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy ParticipantsCOMPLETEDPHASE12023-01-062023-07-052023-07-05
NCT05684289A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)COMPLETEDPHASE12023-01-032023-05-022023-05-02
NCT05369832An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical PracticeTERMINATEDPHASE42022-12-162025-04-112025-01-21
NCT05469737A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)ACTIVE_NOT_RECRUITINGPHASE2, PHASE32022-12-142026-07-292026-01-31
NCT05582395A Study of Mavacamten in Non-Obstructive Hypertrophic CardiomyopathyACTIVE_NOT_RECRUITINGPHASE32022-12-142029-06-292025-03-06
NCT05664737A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-ThalassemiaRECRUITINGPHASE22022-12-092034-08-142027-07-16
NCT05625412A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid TumorsCOMPLETEDPHASE12022-12-092025-05-122025-05-12
NCT05644665A Study to Evaluate Efficacy and Long-term Safety of Oral Ozanimod in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC)TERMINATEDPHASE32022-12-092025-03-072025-03-07
NCT05577715A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)TERMINATEDPHASE22022-11-142024-08-122024-08-12
NCT05615012A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy ParticipantsCOMPLETEDPHASE12022-11-112023-12-132023-12-13
NCT05556265A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia AreataTERMINATEDPHASE22022-11-082024-05-162024-01-06
NCT05579574A Study to Investigate the Interaction of BMS-986322 and a Combined Oral Hormonal Contraceptive (Ethinyl Estradiol [EE]/Norethindrone [NET]) in Healthy Female ParticipantsCOMPLETEDPHASE12022-10-212023-06-012023-06-01
NCT05567510A Study to Evaluate the Metabolism and Excretion of BMS-986369 in Healthy Male ParticipantsCOMPLETEDPHASE12022-10-202022-12-272022-12-27
NCT05372354A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple MyelomaRECRUITINGPHASE1, PHASE22022-10-182026-10-122026-10-12
NCT05567458A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia.ACTIVE_NOT_RECRUITINGPHASE22022-10-172026-08-012025-08-01
NCT05478499Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp PsoriasisCOMPLETEDPHASE42022-10-062024-10-172024-01-11
NCT05543629A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung CancerTERMINATEDPHASE1, PHASE22022-10-042024-09-122024-09-12
NCT05005273A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung CancerCOMPLETEDPHASE22022-10-032022-12-272022-12-27
NCT05546151A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese DescentCOMPLETEDPHASE12022-09-282023-04-072023-04-07
NCT05244070A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTERMINATEDPHASE12022-09-142023-05-042023-05-04
NCT05255601A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin LymphomaRECRUITINGPHASE1, PHASE22022-09-132028-07-052028-07-05
NCT05517837A Phase 1, First-in-Human Study of BMS-986421 in Healthy ParticipantsTERMINATEDEARLY_PHASE12022-09-132023-07-142023-07-14
NCT05350800A Study to Evaluate the Drug Exposure of Single Ascending Doses of BMS-986369 and the Effect of Food on the BMS-986369 in Healthy ParticipantsCOMPLETEDPHASE12022-09-122023-05-042023-05-04
NCT05445440A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of SulfasalazineCOMPLETEDPHASE12022-09-062022-11-232022-11-17
NCT05413018An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete RemissionACTIVE_NOT_RECRUITINGPHASE22022-08-192026-03-012025-10-31
NCT05414175A Study of Mavacamten in Obstructive Hypertrophic CardiomyopathyACTIVE_NOT_RECRUITINGPHASE32022-08-192026-03-062023-11-27
NCT05407675A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid TumorsCOMPLETEDPHASE1, PHASE22022-08-022025-07-242024-08-22
NCT05297565A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete ResectionCOMPLETEDPHASE32022-08-022024-02-082024-02-08
NCT05498480Study of Relatlimab in Combination With Nivolumab in Chinese ParticipantsCOMPLETEDPHASE12022-07-272024-01-182024-01-18
NCT05405543A Study to Evaluate the Safety, Tolerability, and Drug Levels of MYK-224 Administered in Single and Multiple Doses in Healthy Adult Japanese ParticipantsCOMPLETEDPHASE12022-07-122022-12-092022-11-16
NCT05409157A Study to Evaluate the Drug Levels of BMS-986166 in Healthy Male ParticipantsCOMPLETEDPHASE12022-06-172022-10-152022-10-15
NCT05245500Phase 1 Study of MRTX1719 in Solid Tumors With MTAP DeletionRECRUITINGPHASE12022-06-092026-04-302026-04-30
NCT05389722A Study to Assess the Drug Levels of CC-92480 After Coadministration With Rifampin and Itraconazole, and the Drug Levels of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy ParticipantsCOMPLETEDPHASE12022-06-092022-11-122022-11-12
NCT05076175A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative ColitisRECRUITINGPHASE2, PHASE32022-05-302031-08-142026-05-22
NCT05362045A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy ParticipantsCOMPLETEDPHASE12022-05-162022-08-192022-08-19
NCT05236738A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed ConditionsCOMPLETEDPHASE12022-05-132022-07-262022-07-05
NCT05284890A Study to Evaluate the Drug Levels of [14C]CC-99677 in Healthy Male ParticipantsCOMPLETEDPHASE12022-05-122022-07-112022-07-11
NCT05337137A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver CancerACTIVE_NOT_RECRUITINGPHASE1, PHASE22022-05-052025-11-072025-10-15
NCT05337345A Study to Evaluate the Drug Levels of Cendakimab Delivered Subcutaneously in Healthy ParticipantsCOMPLETEDPHASE12022-05-022022-12-152022-12-15
NCT05328908A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal CancerTERMINATEDPHASE32022-04-282025-07-142025-07-14
NCT05304533A Study to Assess the Drug Interaction Between MYK-224 and Itraconazole and Verapamil in Healthy ParticipantsCOMPLETEDPHASE12022-04-212022-11-292022-11-14
NCT05320094A Study to Evaluate the Effect of Activated Charcoal With Sorbitol on the Single-dose of Mavacamten in Healthy ParticipantsCOMPLETEDPHASE12022-04-152022-09-112022-09-11
NCT05303220A Study to Assess Relative Bioavailability of Branebrutinib, From a Tablet Formulation to the Capsule Formulation, the Effect of Food on the Bioavailability of Branebrutinib From a Tablet Formulation, and the Safety and Drug Levels of Branebrutinib From a Tablet Formulation in Healthy ParticipantsCOMPLETEDPHASE12022-04-082022-08-182022-08-18
NCT05298592A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced TumorsCOMPLETEDPHASE12022-03-312024-08-162024-08-16
NCT05093790A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy ParticipantsCOMPLETEDPHASE22022-03-252022-11-142022-11-14
NCT05169684A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate CancerTERMINATEDPHASE22022-02-142023-12-062023-12-06
NCT05136677A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese ParticipantsACTIVE_NOT_RECRUITINGPHASE22022-01-252026-10-082026-10-07
NCT05168202A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic SyndromesTERMINATEDPHASE12022-01-192024-07-302024-07-30
NCT05197426A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete RemissionACTIVE_NOT_RECRUITINGPHASE22022-01-172026-04-302025-01-27
NCT05162222A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Single-dose of Danicamtiv in Healthy ParticipantsCOMPLETEDPHASE12021-12-152022-07-082022-07-08
NCT05064436A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple SclerosisTERMINATEDPHASE12021-12-102023-12-182023-12-18
NCT03978611A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) TreatmentTERMINATEDPHASE12021-12-092023-07-262023-07-26
NCT05134948A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid TumorsACTIVE_NOT_RECRUITINGPHASE1, PHASE22021-11-302025-10-222025-10-22
NCT05002569A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV MelanomaTERMINATEDPHASE32021-10-192025-04-022024-12-16
NCT04895696A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)ACTIVE_NOT_RECRUITINGPHASE22021-10-112029-04-222026-03-29
NCT05025085A Study Investigating AGEN1777 in Participants With Advanced Solid TumorsCOMPLETEDPHASE12021-10-042024-04-012023-07-11
NCT05051553A Study to Evaluate the Bioavailability of Fedratinib When Administered in Different Ways to Healthy Adult ParticipantsCOMPLETEDPHASE12021-09-212022-04-082021-12-23
NCT04909801A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to MethotrexateACTIVE_NOT_RECRUITINGPHASE32021-09-152027-09-012023-06-14
NCT05001152Taste Assessment of OzanimodCOMPLETEDPHASE12021-09-092021-09-272021-09-17
NCT05014438A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic DermatitisCOMPLETEDPHASE22021-08-172022-08-222022-08-22
NCT04943900A Study of BMS-986416 With and Without Nivolumab in Select Solid TumorsCOMPLETEDPHASE12021-08-092025-02-272025-02-27
NCT04934696A Study to Characterize the Drug Levels of an Oral Contraceptive With and Without BMS-986166 in Healthy Female Participants of Childbearing PotentialCOMPLETEDPHASE12021-08-032022-01-252022-01-25
NCT04956627A Study to Assess the Effect of Itraconazole, Phenytoin and Gemfibrozil on the Drug Levels of BMS-986166 in Healthy ParticipantsCOMPLETEDPHASE12021-07-282022-04-272022-04-27
NCT04877288A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive MedicationsRECRUITINGPHASE32021-07-212033-12-302032-12-30
NCT04949269A Study to Evaluate the Drug Levels of Deucravacitinib From Tablets After Oral Administration in Healthy ParticipantsCOMPLETEDPHASE12021-07-202022-01-032022-01-03
NCT04965389A Study of Milvexian Using an IV Microtracer With Additional Formulation and Food Effect Comparison in Healthy ParticipantsCOMPLETEDPHASE12021-07-162021-10-012021-08-22
NCT04908189A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor TreatmentACTIVE_NOT_RECRUITINGPHASE32021-07-152026-11-122024-02-06
NCT04965402A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986166 in Healthy Japanese ParticipantsCOMPLETEDPHASE12021-07-152022-02-072022-02-07
NCT04908202A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic DrugsACTIVE_NOT_RECRUITINGPHASE32021-07-132027-06-102024-09-05
NCT04857034A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)ACTIVE_NOT_RECRUITINGPHASE22021-07-122028-02-282024-08-22
NCT04941755A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy ParticipantsCOMPLETEDPHASE12021-06-252021-09-242021-09-24
NCT04649710A Study to Evaluate the Drug Levels and Safety of Pegbelfermin in Healthy Overweight and Obese Chinese and Korean ParticipantsWITHDRAWNPHASE12021-06-212021-09-222021-09-21
NCT04926051A Study to Assess the Safety, Tolerability and Drug Levels of BMS-986172 in Healthy and Obese Participants, Including an Assessment of the Effects of Food on BMS-986172 AbsorptionCOMPLETEDPHASE12021-06-152021-12-282021-12-28
NCT04730349A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant CancerTERMINATEDPHASE1, PHASE22021-06-032022-06-222022-06-22
NCT04895709A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid TumorsRECRUITINGPHASE1, PHASE22021-05-272028-07-072028-07-07
NCT04882150A Study to Determine the Safety, Drug Levels and Drug Effects of BMS-986196 and Food and Formulation Effects on Relative Absorption Healthy ParticipantsCOMPLETEDPHASE12021-05-272022-06-102022-06-10
NCT04810078A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has SpreadACTIVE_NOT_RECRUITINGPHASE32021-05-212027-05-102025-07-29
NCT04877990A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative ColitisCOMPLETEDPHASE22021-05-072023-08-292023-08-29
NCT04151563A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and ChemotherapyWITHDRAWNPHASE1, PHASE22021-04-152026-05-132023-12-17
NCT04763226A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986308 in Healthy ParticipantsCOMPLETEDPHASE12021-04-142022-02-272022-02-27
NCT04464577A Study to Evaluate the Effect of Fluconazole, Bupropion, or Itraconazole on the Drug Levels and Safety of BMS-986235WITHDRAWNPHASE12021-04-012021-06-082021-06-07
NCT04495010Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma ParticipantsWITHDRAWNPHASE22021-03-312027-10-232024-02-28
NCT04766892A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnTCOMPLETEDPHASE22021-03-302024-02-262024-02-26
NCT04772079A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque PsoriasisRECRUITINGPHASE32021-03-232033-09-082029-01-01
NCT04817007A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)ACTIVE_NOT_RECRUITINGPHASE1, PHASE22021-03-222026-05-312026-05-31
NCT04702880A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung CancerACTIVE_NOT_RECRUITINGPHASE22021-03-172025-12-312025-12-31
NCT04267393Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)TERMINATEDPHASE22021-03-172024-02-092023-08-16
NCT04613518A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative ColitisCOMPLETEDPHASE22021-03-152023-11-292023-05-31
NCT04736134A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Healthy ParticipantsCOMPLETEDPHASE12021-03-032024-03-142024-03-14
NCT04766476A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver DiseaseTERMINATEDPHASE12021-02-242021-08-122021-08-12
NCT04623775A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)ACTIVE_NOT_RECRUITINGPHASE22021-02-172026-01-302024-01-11
NCT04684654BMS-986325 in Healthy Participants and Participants With Primary Sjögren's SyndromeTERMINATEDPHASE12021-02-162023-07-252023-07-25
NCT04567615A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase InhibitorsACTIVE_NOT_RECRUITINGPHASE22021-02-042025-10-032023-08-31
NCT03770299An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual DiseaseWITHDRAWNPHASE22021-01-152024-03-142023-03-14
NCT04671953Effect of BMS-986165 on the Blood Levels of MetforminCOMPLETEDPHASE12020-12-182021-03-302021-03-03
NCT04513522A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in IndiaCOMPLETEDPHASE42020-12-172024-01-042024-01-04
NCT04634149A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver ImpairmentCOMPLETEDPHASE12020-11-232022-06-022022-06-02
NCT04318093Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart FailureCOMPLETEDPHASE22020-11-062021-07-192021-07-19
NCT04567667Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986278 in Healthy Male ParticipantsCOMPLETEDPHASE12020-10-152021-04-112021-04-11
NCT04472494Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory CompromiseTERMINATEDPHASE22020-10-142021-09-132021-08-12
NCT04132817A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has SpreadCOMPLETEDPHASE12020-09-222022-08-152022-08-15
NCT04550195A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986337 When Taken by Mouth by Healthy ParticipantsCOMPLETEDPHASE12020-09-172021-03-032021-03-03
NCT04340193A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver CancerCOMPLETEDPHASE32020-09-142023-12-122023-12-12
NCT04540705A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has SpreadCOMPLETEDPHASE12020-09-112024-01-182024-01-18
NCT04536961A Study to Evaluate the Drug Levels of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy ParticipantsCOMPLETEDPHASE12020-09-102020-12-252020-12-25
NCT04088500A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell CarcinomaTERMINATEDPHASE22020-09-032021-11-152021-11-15
NCT04305899A Study to Compare the Taste and Levels in Blood Plasma of BMS-986165 When Taken as Different Formulations by Healthy Adult ParticipantsCOMPLETEDPHASE12020-08-312020-11-252020-11-25
NCT04493541A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus ErythematosusCOMPLETEDPHASE12020-08-262023-04-212023-04-21
NCT04572893Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other CausalitiesTERMINATEDPHASE22020-08-042024-02-222024-02-22
NCT04515628Study to Assess the Effect of Branebrutinib on the Drug Levels of Rosuvastatin in Healthy ParticipantsCOMPLETEDPHASE12020-08-022020-10-262020-10-18
NCT04308681A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung FibrosisCOMPLETEDPHASE22020-07-292023-09-222022-08-04
NCT04493567Relative Levels of BMS-986036 in Blood Plasma in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration Via Auto-injector Versus Pre-filled SyringeCOMPLETEDPHASE12020-07-292021-06-112021-06-11
NCT04470778Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy ParticipantsCOMPLETEDPHASE12020-07-202021-03-282021-03-21
NCT04349267Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid TumorsTERMINATEDPHASE1, PHASE22020-07-142024-08-222024-08-22
NCT04468815A Study to Assess the Levels in Blood Plasma of BMS-986278 in Healthy Participants Following Administration of Tablets, With or Without Food, and in the Presence of an Antacid (Esomeprazole)COMPLETEDPHASE12020-07-102020-10-072020-10-07
NCT04349072A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction TherapyCOMPLETEDPHASE32020-07-062024-05-202022-02-07
NCT04311710A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor TypesTERMINATEDPHASE12020-06-252023-01-182021-01-14
NCT04444050Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986331 in Healthy ParticipantsCOMPLETEDPHASE12020-06-232021-05-192021-05-19
NCT04301310Study to Evaluate the Effect of Rifampin on the Drug Levels in Blood and Safety of BMS-986235 in Healthy ParticipantsWITHDRAWNPHASE12020-03-092020-03-162020-03-16
NCT04263350A Study to Examine the Acceptable Taste and to Estimate the Amount of Atazanavir and Cobicistat in the Body When Taken as a Combination Product Versus When Taken as Separate Products at the Same TimeCOMPLETEDPHASE12020-02-262020-11-172020-11-12
NCT04237831A Study to Evaluate the Pharmacokinetics (Drug Levels and Metabolism), Safety, and Tolerability of BMS-986259 in Participants With Various Levels of Kidney FunctionCOMPLETEDPHASE12020-02-262021-07-162021-07-16
NCT04269356Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male ParticipantsCOMPLETEDPHASE12020-02-182021-03-302021-03-30
NCT04100018A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate CancerCOMPLETEDPHASE32020-02-062024-06-252023-06-01
NCT04249284Pharmacokinetics (Drug Levels in Blood) of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy ParticipantsCOMPLETEDPHASE12020-02-062020-03-152020-03-15
NCT04209114A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder CancerCOMPLETEDPHASE32020-02-052023-06-072023-06-07
NCT04225936A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver ImpairmentCOMPLETEDPHASE12020-01-162021-06-012021-06-01
NCT04149574A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)TERMINATEDPHASE32020-01-152023-10-312023-10-31
NCT04186871Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid ArthritisCOMPLETEDPHASE22020-01-072022-12-052022-12-05
NCT04209699A Study Comparing the Effects of Famotidine Pretreatment and of Food on the Relative Bioavailability of BMS-986165 in Healthy VolunteersCOMPLETEDPHASE12019-12-272020-02-112020-02-04
NCT04126486A Study to Determine if Identification of Undiagnosed Atrial Fibrillation in People at Least 70 Years of Age Reduces the Risk of StrokeCOMPLETEDPHASE42019-12-172023-06-302023-06-30
NCT04154800A Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of Single and Multiple Doses of BMS-986209 in Healthy ParticipantsCOMPLETEDPHASE12019-12-062021-08-312021-08-31
NCT04167462An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South KoreaCOMPLETEDPHASE32019-11-252022-01-072021-03-08
NCT04109066Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast CancerCOMPLETEDPHASE32019-11-182023-12-272023-01-16
NCT04175925A Study Assessing the Drug Levels, Drug Effects, and Safety of BMS-986322 in Healthy ParticipantsCOMPLETEDPHASE12019-11-152021-07-132021-07-13
NCT04025879A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung CancerACTIVE_NOT_RECRUITINGPHASE32019-11-052027-07-302023-07-26
NCT03704077An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction AdenocarcinomaWITHDRAWNPHASE22019-10-312024-09-302022-02-27
NCT04099251Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C MelanomaACTIVE_NOT_RECRUITINGPHASE32019-10-282027-06-292022-06-28
NCT04075604A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast CancerCOMPLETEDPHASE22019-10-182021-07-272021-07-27
NCT04026412A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by SurgeryCOMPLETEDPHASE32019-10-082024-11-262024-03-22
NCT04124003A Study to Assess the Drug-drug Interaction of BMS-963272 and RosuvastatinCOMPLETEDPHASE12019-10-082020-01-032020-01-03
NCT04112498A Phase 1, Bioavailability Study of Relatlimab in Combination With NivolumabCOMPLETEDPHASE12019-10-012023-02-272023-02-27
NCT04069143A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327COMPLETEDPHASE12019-10-012022-07-122022-07-12
NCT04113668The Effects Diflunisal on the Levels of BMS-986165 in Healthy ParticipantsCOMPLETEDPHASE12019-10-012019-11-252019-11-19
NCT04039607A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular CarcinomaACTIVE_NOT_RECRUITINGPHASE32019-09-302026-09-302026-09-30
NCT04116632A Multiple Dose Study to Assess the Safety and Tolerability of BMS-963272 in Obese But Otherwise Healthy AdultsCOMPLETEDPHASE12019-09-302020-02-102020-02-10
NCT04086719An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition.COMPLETEDPHASE12019-09-122019-10-292019-10-29
NCT03994601An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid CancersCOMPLETEDPHASE1, PHASE22019-09-062024-08-312024-08-31
NCT04065932A Study to Determine the Pharmacokinetic Profile of BMS-986165 TabletsCOMPLETEDPHASE12019-08-222019-12-102019-12-08
NCT04055506A Study to Investigate the Effects of Cytochrome P450 1A2 Induction by Ritonavir on BMS-986165 Drug Levels and Effects in Healthy ParticipantsCOMPLETEDPHASE12019-08-142019-09-212019-09-21
NCT04036435Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With PsoriasisACTIVE_NOT_RECRUITINGPHASE32019-08-122026-07-262026-07-25
NCT03899155Pan Tumor Rollover StudyRECRUITINGPHASE22019-08-092029-08-252029-08-25
NCT04008030A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)ACTIVE_NOT_RECRUITINGPHASE32019-08-052026-06-102024-08-28
NCT04016753A Study Measuring the Effectiveness of BMS-986256 Combined With Oral Contraceptive in Healthy Female ParticipantsCOMPLETEDPHASE12019-08-052020-02-212020-02-21
NCT04039373Effects of BMS-986256 at Steady State on the Single Dose Pharmacokinetics of Mycophenolate MofetilCOMPLETEDPHASE12019-07-222019-10-162019-09-18
NCT04082741A Single and Multiple Ascending Dose Study of BMS-986318 in Healthy ParticipantsWITHDRAWNPHASE12019-07-182019-09-122019-09-12
NCT03943147An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus NephritisTERMINATEDPHASE22019-07-152021-09-172020-10-29
NCT03934216Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative ColitisCOMPLETEDPHASE22019-07-012023-04-042021-06-13
NCT03980314A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete ResectionCOMPLETEDPHASE12019-06-242023-11-062021-03-04
NCT03873402A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney CancerACTIVE_NOT_RECRUITINGPHASE32019-06-212025-08-292025-08-29
NCT04008992An Ascending Dose Study of BMS-986259 to Study Safety in Healthy ParticipantsCOMPLETEDPHASE12019-06-182021-01-042021-01-04
NCT03979248A Study to Investigate the Effects of Gastric Acid Suppression by Rabeprazole and BMS-986165 on How Fast and Complete The Drug is Absorbed Into the Body of Healthy ParticipantsCOMPLETEDPHASE12019-05-162019-07-072019-07-07
NCT03981094A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy ParticipantsCOMPLETEDPHASE12019-05-102019-07-302019-07-27
NCT03936374A Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of BMS-986205 in Healthy ParticipantsCOMPLETEDPHASE12019-05-082019-07-202019-07-20
NCT03950960A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of BMS-986256 in Healthy ParticipantsCOMPLETEDPHASE12019-05-022019-08-072019-07-31
NCT03939702Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male ParticipantsCOMPLETEDPHASE12019-05-022019-07-112019-07-11
NCT03930602Study to Characterize the Effects of Cytochrome p450 1A2 Inhibition on Systemic Exposure to BMS-986165COMPLETEDPHASE12019-05-012019-05-272019-05-27
NCT03924427An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe PsoriasisCOMPLETEDPHASE32019-04-102021-03-242021-03-24
NCT03745807An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid TumorsCOMPLETEDPHASE12019-04-092019-12-182019-12-18
NCT03890770A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease.COMPLETEDPHASE12019-04-042020-02-132020-02-07
NCT03956953Single and Multiple Dose Pharmacokinetics of BMS-986165 in a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Chinese SubjectsCOMPLETEDPHASE12019-04-042019-09-252019-09-25
NCT03881059Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)COMPLETEDPHASE22019-04-012021-01-272020-04-27
NCT03920267Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus ErythematosusCOMPLETEDPHASE22019-03-262025-03-212025-03-21
NCT03956680An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid CancersCOMPLETEDPHASE12019-03-262024-04-242024-04-17
NCT03891108A Pharmacokinetics, Safety and Tolerability Study of Multiple Formulations of BMS-986231 in Healthy ParticipantsCOMPLETEDPHASE12019-02-282019-07-292019-07-29
NCT03890809An Investigational Study of BMS-986165 in Participants With Normal Liver Function and Participants With Mild to Severe Liver DamageCOMPLETEDPHASE12019-02-262019-11-302019-11-30
NCT03766581A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and ClopidogrelCOMPLETEDPHASE22019-01-272022-03-312022-03-31
NCT03873415Assessment of Gut Absorption of Experimental Medication BMS-986165 in Healthy MalesCOMPLETEDPHASE12019-01-252019-05-012019-05-01
NCT03730961An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop DiureticCOMPLETEDPHASE22019-01-172020-01-092019-12-11
NCT03834662A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients MalignanciesCOMPLETEDPHASE12019-01-072020-02-192020-02-19
NCT03831438Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic SclerosisCOMPLETEDPHASE12019-01-012020-06-202020-06-20
NCT03792750A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid TumorsCOMPLETEDPHASE1, PHASE22018-12-312020-12-182020-12-18
NCT03739788An Investigational Study to Evaluate Experimental Medication BMS-986165 Given as a Tablet and Solution in Healthy Male ParticipantsCOMPLETEDPHASE12018-12-052019-02-112019-02-11
NCT03714022A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different ProcessesCOMPLETEDPHASE12018-11-092019-04-022019-04-02
NCT03661320A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder CancerACTIVE_NOT_RECRUITINGPHASE32018-11-062027-12-302025-11-17
NCT03668119A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)COMPLETEDPHASE22018-10-312023-08-022022-05-03
NCT03656718A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)COMPLETEDPHASE1, PHASE22018-10-292024-09-122022-09-07
NCT03662659An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) CancersCOMPLETEDPHASE22018-10-162024-01-182020-08-27
NCT03751228A Taste Assessment of BMS-986165 in Healthy ParticipantsCOMPLETEDPHASE12018-10-112018-11-262018-11-26
NCT03698513A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy SubjectsCOMPLETEDPHASE12018-10-042019-02-192019-02-19
NCT03723655A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCMACTIVE_NOT_RECRUITINGPHASE2, PHASE32018-09-272026-01-162026-01-16
NCT03635983A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic MelanomaCOMPLETEDPHASE32018-09-212024-03-192021-11-19
NCT03661632An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid TumorsCOMPLETEDPHASE12018-09-112020-12-292019-11-11
NCT03674476An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney FunctionCOMPLETEDPHASE12018-09-112019-06-242019-06-24
NCT03712540An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy ParticipantsCOMPLETEDPHASE12018-09-062018-11-082018-11-08
NCT03634995An Investigational Study to Evaluate the Effects of Experimental Medication BMS-986256 in Healthy ParticipantsCOMPLETEDPHASE12018-08-142019-10-092019-10-09
NCT03634969An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired ParticipantsCOMPLETEDPHASE12018-08-142019-04-302019-04-30
NCT03660436An Investigational Study of Experimental Medication BMS-986165 in Healthy ParticipantsCOMPLETEDPHASE12018-08-142018-10-182018-10-10
NCT03624127Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With PsoriasisCOMPLETEDPHASE32018-08-072020-09-022020-09-02
NCT03519256A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the BladderTERMINATEDPHASE22018-08-022022-08-242022-08-22
NCT03611751An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque PsoriasisCOMPLETEDPHASE32018-07-262020-11-302020-11-29
NCT03599622An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's DiseaseTERMINATEDPHASE22018-07-162023-10-232022-12-12
NCT03487848Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) InfectionTERMINATEDPHASE22018-06-252020-09-172018-10-18
NCT03486899A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver FibrosisCOMPLETEDPHASE22018-06-192021-08-172020-09-14
NCT03486912A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver CirrhosisCOMPLETEDPHASE22018-06-122021-09-142020-10-08
NCT03563950An Investigational Study to Evaluate the Effect of Rifampin on the Singe Dose of Experimental Medication BMS-986224 in Healthy ParticipantsCOMPLETEDPHASE12018-06-012018-07-272018-07-27
NCT03459222An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have SpreadCOMPLETEDPHASE1, PHASE22018-05-302025-02-192025-02-19
NCT03541564An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram EffectsCOMPLETEDPHASE12018-05-302018-09-042018-09-04
NCT03515980An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver FunctionCOMPLETEDPHASE12018-05-252019-08-292019-08-29
NCT03417037An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung CancerWITHDRAWNPHASE32018-05-242025-08-202021-04-25
NCT03335540An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker AssessmentCOMPLETEDPHASE12018-05-072021-08-252021-03-31
NCT03496168Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEERCOMPLETEDPHASE22018-04-262023-11-092023-11-09
NCT03509883Bioavailability of Apixaban Sprinkle Compared to Apixaban CapsulesCOMPLETEDPHASE12018-04-262018-06-152018-06-15
NCT03383458A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or AblationACTIVE_NOT_RECRUITINGPHASE32018-04-182025-12-162025-04-28
NCT03470922A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced MelanomaACTIVE_NOT_RECRUITINGPHASE2, PHASE32018-04-112030-12-152021-01-25
NCT03444753An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be RemovedTERMINATEDPHASE12018-04-052022-02-142022-02-14
NCT03386838An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and NeckWITHDRAWNPHASE32018-03-282018-04-192018-04-19
NCT03332186A Study of Experimental Medication BMS-986231 in Patients With Different Levels of Kidney FunctionCOMPLETEDPHASE12018-03-152018-10-222018-10-22
NCT03048136A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung CancerWITHDRAWNPHASE32018-03-092019-09-292019-09-29
NCT03446040An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have SpreadTERMINATEDPHASE1, PHASE22018-03-082024-08-292024-08-29
NCT03444766Study of Nivolumab for Advanced Cancers in IndiaCOMPLETEDPHASE42018-03-062019-07-172019-07-17
NCT03419910An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male ParticipantsCOMPLETEDPHASE12018-03-052018-05-042018-05-04
NCT02982707Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy ParticipantsCOMPLETEDPHASE12018-03-012018-09-282018-09-28
NCT03414983An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has SpreadCOMPLETEDPHASE2, PHASE32018-02-202022-12-282021-02-01
NCT03420768A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis CCOMPLETEDPHASE22018-02-142019-05-282018-12-10
NCT03445208A Study of Experimental Medication BMS-986036 Given to Healthy ParticipantsCOMPLETEDPHASE12018-02-142018-05-022018-05-02
NCT03400332A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced CancersACTIVE_NOT_RECRUITINGPHASE1, PHASE22018-02-122025-11-302024-04-26
NCT03429933A Study of Experimental Medication BMS-986278 Given to Healthy ParticipantsCOMPLETEDPHASE12018-02-072019-03-022019-03-02
NCT03447990v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491COMPLETEDPHASE1, PHASE22018-02-062019-10-242019-10-24
NCT03377361An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has SpreadCOMPLETEDPHASE1, PHASE22018-01-312024-11-042024-11-04
NCT03402087A Study to Investigate BMS-986165 and Methotrexate in Healthy Male PatientsCOMPLETEDPHASE12018-01-082018-03-252018-03-20
NCT03374228A Study to Evaluate the Bioavailability of BMS-986205COMPLETEDPHASE12018-01-042018-02-162018-02-16
NCT03195491A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in AsiaCOMPLETEDPHASE32017-12-252021-06-082021-06-08
NCT03378310A Study in Healthy Participants Evaluating the Absorption of a BMS-986205 Tablet Into the Bloodstream Compared to a Reference TabletCOMPLETEDPHASE12017-12-212018-02-222018-02-15
NCT03338790An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate CancerCOMPLETEDPHASE22017-12-192025-01-102021-01-13
NCT03336216A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic CancerCOMPLETEDPHASE22017-12-182023-06-012023-06-01
NCT03349710Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck CancerCOMPLETEDPHASE32017-12-152019-10-142019-10-14
NCT03369223A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid TumorsCOMPLETEDPHASE1, PHASE22017-12-062024-11-072024-11-07
NCT03363776An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial CancersTERMINATEDPHASE1, PHASE22017-12-062019-11-222019-11-22
NCT03375138A Study Using Healthy Volunteers Comparing Belatacept Which Has Been Manufactured By 2 Different ProcessesCOMPLETEDPHASE12017-12-042019-04-022018-05-08
NCT03329846An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced MelanomaCOMPLETEDPHASE32017-11-302020-07-022020-07-02
NCT03357731A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic FunctionCOMPLETEDPHASE22017-11-302019-05-102019-05-10
NCT03351231An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced CancerTERMINATEDPHASE1, PHASE22017-11-272018-08-282018-08-28
NCT03346837A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy SubjectsCOMPLETEDPHASE12017-11-222017-12-202017-12-20
NCT03335553A Study of Experimental Medication BMS-986235 in Healthy SubjectsCOMPLETEDPHASE12017-11-152021-07-022021-07-02
NCT03362437Evaluate the Pharmacokinetics of BMS-986177 From Two Formulations in Healthy ParticipantsCOMPLETEDPHASE12017-11-152017-12-282017-12-28
NCT03362411A Study to Assess the Absorption of a Single Dose of BMS-986205 in Healthy Volunteers When Administered as a Crushed Tablet Orally or Crushed Tablet Suspension Via Nasogastric Tube, as Compared to a TabletCOMPLETEDPHASE12017-11-092018-02-012018-02-01
NCT03329885A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious PsoriasisTERMINATEDPHASE1, PHASE22017-11-022018-06-262018-06-26
NCT03341390An Investigational Study to Assess the Effect of BMS-986177 on Aspirin in Healthy ParticipantsCOMPLETEDPHASE12017-10-182017-11-162017-11-16
NCT03312426An Investigational Study to Assess the Effect of a Light Meal and a High-Fat Meal on the Absorption of BMS-986205 in Healthy ParticipantsCOMPLETEDPHASE12017-10-092017-11-222017-11-22
NCT03281122A Study of BMS-986224 in Healthy Subjects and Heart Failure Patients With Reduced Ejection FractionTERMINATEDPHASE12017-09-222019-04-172019-04-17
NCT03252587An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus ErythematosusCOMPLETEDPHASE22017-09-212021-10-282021-06-29
NCT03254784A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet FormulationCOMPLETEDPHASE12017-09-132017-11-152017-11-04
NCT03262740The Effect of BMS-986195 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female PatientsCOMPLETEDPHASE12017-09-112018-01-302017-12-19
NCT03251924A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid TumorsTERMINATEDPHASE1, PHASE22017-09-012021-12-202021-12-20
NCT03262727The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female PatientsCOMPLETEDPHASE12017-09-012017-12-192017-11-23
NCT03215706A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLCCOMPLETEDPHASE32017-08-242024-10-182019-08-16
NCT03245515A Study of BMS-986195 in Healthy Male SubjectsCOMPLETEDPHASE12017-08-152017-10-052017-09-22
NCT03184870A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid TumorsCOMPLETEDPHASE1, PHASE22017-08-082023-06-142023-04-06
NCT03195478A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid TumorsCOMPLETEDPHASE1, PHASE22017-08-022024-01-052024-01-05
NCT03141177A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell CarcinomaACTIVE_NOT_RECRUITINGPHASE32017-07-232026-01-162020-02-12
NCT03247283Pharmacokinetics and Metabolism Study in Healthy Male ParticipantsCOMPLETEDPHASE12017-07-192017-10-152017-10-15
NCT03192969A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA)WITHDRAWNPHASE32017-07-152021-11-232020-06-07
NCT03203876A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid TumorsCOMPLETEDPHASE12017-07-142020-08-062020-08-06
NCT03196206Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal ImpairmentCOMPLETEDPHASE12017-07-132018-03-042018-03-04
NCT03138512A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a KidneyCOMPLETEDPHASE32017-07-072024-02-012023-09-28
NCT03143153A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus CisplatinCOMPLETEDPHASE32017-06-292025-01-132021-01-18
NCT03198182A Study to Test the Effects of BMS-986036 on the Body in Healthy Japanese and Non-Japanese SubjectsCOMPLETEDPHASE12017-06-282017-09-222017-09-22
NCT03224260To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese ParticipantsCOMPLETEDPHASE12017-06-282017-11-072017-11-07
NCT03138499A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,TERMINATEDPHASE32017-06-262021-02-222021-02-22
NCT03192943A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced TumorsCOMPLETEDPHASE12017-06-232018-12-112018-12-11
NCT03210909Pharmacokinetics and Metabolism of [14C] BMS-986231 in Healthy Male ParticipantsCOMPLETEDPHASE12017-06-222017-07-202017-07-20
NCT03098550A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have SpreadCOMPLETEDPHASE1, PHASE22017-06-152020-07-062020-07-06
NCT03130959A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) MalignanciesCOMPLETEDPHASE22017-06-122022-01-172020-03-10
NCT03090737Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung CancerCOMPLETEDPHASE22017-06-022022-03-142021-02-16
NCT03158272A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has SpreadCOMPLETEDPHASE12017-05-252019-10-232019-10-23
NCT03000673A Study to Evaluate Safety of Single Doses of BMS-986177 in Patients With End Stage Renal Disease (ESRD) Treated With HemodialysisCOMPLETEDPHASE1, PHASE22017-05-232017-10-232017-10-23
NCT03083821A Study to Provide a Better Understanding of Baraclude's Pharmacokinetic Properties in a Real World Clinical SettingCOMPLETEDPHASE12017-05-162017-12-192017-12-19
NCT03131973Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and PravastatinCOMPLETEDPHASE12017-05-132017-11-102017-11-05
NCT03142165A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy ParticipantsCOMPLETEDPHASE12017-05-112017-11-292017-11-29
NCT03110107First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid TumorsTERMINATEDPHASE1, PHASE22017-05-042024-04-042024-04-04
NCT02971683Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory MyopathyCOMPLETEDPHASE32017-05-042022-08-022020-07-27
NCT03068455An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV MelanomaCOMPLETEDPHASE32017-04-112021-02-022020-06-12
NCT03001882An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)COMPLETEDPHASE22017-03-292023-04-242022-02-17
NCT02927769A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line TreatmentCOMPLETEDPHASE22017-03-282024-05-282024-05-28
NCT02985957A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)COMPLETEDPHASE22017-03-262025-01-072022-04-05
NCT03036098Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial CancerACTIVE_NOT_RECRUITINGPHASE32017-03-242025-11-242024-08-30
NCT02864251A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) TherapyCOMPLETEDPHASE32017-03-172022-10-172022-01-20
NCT02998528A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)COMPLETEDPHASE32017-03-042024-12-062021-09-08
NCT03029780An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell CarcinomaCOMPLETEDPHASE22017-02-162021-06-152017-11-27
NCT02996110A Study to Test Combination Treatments in People With Advanced Renal Cell CarcinomaCOMPLETEDPHASE22017-02-022021-11-232021-11-23
NCT03044873Effect of BMS-986165 on the Pharmacokinetics of RosuvastatinCOMPLETEDPHASE12017-02-022017-03-272017-03-14
NCT03038711A Multiple Dose Study to Assess the Safety and Tolerability of BMS-986166 in Healthy VolunteersCOMPLETEDPHASE12017-02-012017-08-102017-08-10
NCT03004768Pharmacokinetics and Metabolism of [14C]BMS-986165 in Healthy Male ParticipantsCOMPLETEDPHASE12017-01-262017-02-272017-02-27
NCT03035734Evaluate the Bioavailability Between 2 BMS-986141 Formulations in Healthy ParticipantsWITHDRAWNPHASE12017-01-252017-02-072017-02-07
NCT03058822Relative Bioavailability of BMS-931699 From Prefilled Syringe Compared to Drug in VialTERMINATEDPHASE12017-01-252017-03-302017-03-30
NCT02981472A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring AnticoagulationCOMPLETEDPHASE22017-01-192021-10-182021-10-18
NCT02982954A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell CancerCOMPLETEDPHASE42017-01-162021-10-062020-05-11
NCT03016325Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart FailureCOMPLETEDPHASE22017-01-132019-11-122019-06-23
NCT02985632A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy ParticipantsWITHDRAWNPHASE12017-01-112017-07-072017-05-18
NCT02966548Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid TumorsCOMPLETEDPHASE12017-01-042024-07-092024-07-09
NCT02960854A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.COMPLETEDPHASE12016-12-072018-01-052018-01-05
NCT02915159A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens SyndromeCOMPLETEDPHASE32016-12-062019-07-232018-08-07
NCT02913313A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid TumorsCOMPLETEDPHASE1, PHASE22016-11-302024-01-252024-01-25
NCT02899299Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma PatientsCOMPLETEDPHASE32016-11-292023-04-282020-03-25
NCT02935634A Study to Test Combination Treatments in Participants With Advanced Gastric CancerCOMPLETEDPHASE22016-11-292022-05-112022-05-11
NCT02949895Study of BMS-986012 in Subjects With Small Cell Lung CanerCOMPLETEDPHASE12016-11-292017-08-292017-08-29
NCT02815592Trial of BMS-986012 in Combination With Platinum and EtoposideCOMPLETEDPHASE12016-11-282024-08-062019-12-15
NCT02931838Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe PsoriasisCOMPLETEDPHASE22016-11-152017-11-162017-11-16
NCT02823574Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCOMPLETEDPHASE22016-11-082022-04-212019-01-23
NCT02902679A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis TreatmentCOMPLETEDPHASE12016-112017-062017-06
NCT02957448A Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics (PK) of BMS-986141 in Healthy SubjectsCOMPLETEDPHASE12016-112017-012017-01
NCT02959060A Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics of BMS-986177 in Healthy SubjectsCOMPLETEDPHASE12016-112016-122016-12
NCT02905266A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With MelanomaCOMPLETEDPHASE32016-10-272019-10-252017-10-23
NCT02857426A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)COMPLETEDPHASE22016-10-212020-11-242019-06-11
NCT02843659Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's SyndromeTERMINATEDPHASE22016-10-182017-07-242017-07-24
NCT02884726Phase 1 Study of Mesothelin-ADCCOMPLETEDPHASE12016-10-142017-09-062017-09-06
NCT02872116Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction CancerCOMPLETEDPHASE32016-10-122024-06-062020-05-27
NCT02741570Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCOMPLETEDPHASE32016-10-052022-09-222021-05-10
NCT02869789An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced CancersCOMPLETEDPHASE42016-10-052022-05-132022-05-13
NCT02932969Study With Healthy Japanese and Non-Asian Participants With BMS-986231COMPLETEDPHASE12016-10-042017-05-262017-05-26
NCT02864264Single Ascending Dose and Multiple Ascending Dose Study in Healthy Participants and Proof of Mechanism Study in Patients With Ulcerative ColitisTERMINATEDPHASE12016-09-142017-09-272017-09-27
NCT02922452A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy SubjectsCOMPLETEDPHASE12016-092016-112016-11
NCT02912234Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy ParticipantsCOMPLETEDPHASE12016-092016-102016-10
NCT03241264A Study of Safety, Tolerability, and the Effects Two ND-L02-s0201 Have on the BodyCOMPLETEDPHASE12016-08-282016-10-212016-10-21
NCT02828124A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver CancerTERMINATEDPHASE1, PHASE22016-08-232018-01-082018-01-08
NCT02705989Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy SubjectsCOMPLETEDPHASE12016-08-182017-08-162017-08-16
NCT02763761An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or OpdivoWITHDRAWNPHASE22016-08-162017-03-312017-03-31
NCT02726581An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple MyelomaCOMPLETEDPHASE32016-08-102022-03-092022-03-09
NCT02880670Pharmacokinetics and Metabolism Study of Radiolabeled BMS-986142 in Healthy Male SubjectsCOMPLETEDPHASE12016-082016-092016-09
NCT02790125A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy SubjectsCOMPLETEDPHASE12016-07-282017-11-072017-11-07
NCT02719613Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating ElotuzumabACTIVE_NOT_RECRUITINGPHASE22016-07-152025-11-132025-11-13
NCT02743494An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction CancerACTIVE_NOT_RECRUITINGPHASE32016-07-142025-10-112020-05-12
NCT02807909A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Pharmacokinetics of BMS-986177 in Healthy SubjectsCOMPLETEDPHASE12016-072016-082016-08
NCT02754141An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With NivolumabCOMPLETEDPHASE1, PHASE22016-06-212021-10-122021-10-12
NCT02737475An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have SpreadCOMPLETEDPHASE1, PHASE22016-06-172020-11-022020-11-02
NCT02713867A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 WeeksCOMPLETEDPHASE32016-05-242022-01-182019-07-15
NCT02763969Safety Study of BMS-986202 in Healthy Subjects and to Treat PsoriasisCOMPLETEDPHASE12016-05-182016-12-152016-12-15
NCT02667587An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)COMPLETEDPHASE32016-05-092024-04-092020-12-22
NCT02750514An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung CancerTERMINATEDPHASE22016-05-092020-01-292020-01-29
NCT02832180The Effect of BMS-986142 on the Pharmacokinetics of a Combined Oral Contraceptive (OC) Containing Ethinyl Estradiol (EE) and Norethindrone Acetate (NET) in Healthy Female SubjectsCOMPLETEDPHASE12016-052016-102016-10
NCT02762123A Study to Assess the Effect of BMS-986142 on Pharmacokinetics (PK) of Probe SubstratesCOMPLETEDPHASE12016-052016-082016-08
NCT02671461Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"COMPLETEDPHASE22016-04-252017-03-312017-03-31
NCT02739373Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of BMS-986189 in Healthy SubjectsCOMPLETEDPHASE12016-04-182016-12-142016-12-14
NCT02658890An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have SpreadCOMPLETEDPHASE1, PHASE22016-04-142021-10-262021-10-26
NCT02714218A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic MelanomaCOMPLETEDPHASE32016-04-042021-05-282017-04-20
NCT02632409An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the CancerACTIVE_NOT_RECRUITINGPHASE32016-03-222027-05-272020-07-17
NCT02654132An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)COMPLETEDPHASE22016-03-182021-10-212018-01-17
NCT02673489A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C InfectionCOMPLETEDPHASE32016-03-152017-05-262017-03-02
NCT02592798Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)COMPLETEDPHASE22016-03-092020-01-282020-01-28
NCT02617589An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)COMPLETEDPHASE32016-03-012022-03-042019-01-17
NCT02832167An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have SpreadCOMPLETEDPHASE22016-02-222021-06-242019-10-20
NCT02638948Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid ArthritisCOMPLETEDPHASE22016-02-162018-05-032018-05-03
NCT02659059Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung CancerCOMPLETEDPHASE22016-02-152022-03-072018-06-22
NCT02581631An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin LymphomasCOMPLETEDPHASE1, PHASE22016-02-112022-02-072020-01-16
NCT02612779A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.COMPLETEDPHASE22016-02-092020-06-122019-07-29
NCT02588625A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)WITHDRAWNPHASE22016-022019-102019-10
NCT02596035An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell CarcinomaCOMPLETEDPHASE42016-01-082021-05-242018-03-19
NCT02593786A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid TumorsCOMPLETEDPHASE1, PHASE22016-01-072021-09-272021-09-27
NCT02137239Regimen Optimization StudyCOMPLETEDPHASE22015-12-312019-05-022019-05-02
NCT02608970Safety and Tolerability Study of BMS-986177 in Healthy SubjectsCOMPLETEDPHASE12015-12-312017-07-232017-07-23
NCT02599402Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced MelanomaCOMPLETEDPHASE32015-12-202020-02-102020-02-10
NCT02613507Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung CancerCOMPLETEDPHASE32015-12-112023-11-242017-09-15
NCT02576509An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular CarcinomaCOMPLETEDPHASE32015-12-072024-02-072019-05-30
NCT02576457Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe SepsisTERMINATEDPHASE12015-12-022017-03-152017-03-15
NCT02551861A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3WITHDRAWNPHASE22015-122017-062016-06
NCT02556086A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1)WITHDRAWNPHASE22015-122017-072016-06
NCT02574078A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)COMPLETEDPHASE1, PHASE22015-11-232020-04-152020-04-15
NCT02464969Apixaban for the Acute Treatment of Venous Thromboembolism in ChildrenCOMPLETEDPHASE42015-11-222024-04-302024-04-30
NCT02557100Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid ArthritisCOMPLETEDPHASE42015-11-192019-03-282019-03-28
NCT02534506Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant TumorsCOMPLETEDPHASE12015-11-062016-11-112016-11-11
NCT02545075A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. DacarbazineCOMPLETEDPHASE32015-10-312019-04-192019-04-19
NCT02538874A Study of BMS-986171 in Healthy People to Assess Safety, to Measure Blood Levels of Drug, and to Find Out What the Drug Does to the BodyCOMPLETEDPHASE12015-10-312016-11-052016-11-04
NCT02369653A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With AsparaginaseCOMPLETEDPHASE32015-10-222021-07-072021-07-07
NCT02516527A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid TumorsCOMPLETEDPHASE12015-10-162018-09-202018-09-20
NCT02598960An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.COMPLETEDPHASE1, PHASE22015-10-142019-12-162019-12-16
NCT02488759An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated TumorsCOMPLETEDPHASE1, PHASE22015-10-132022-10-242021-03-19
NCT02538666An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based ChemotherapyCOMPLETEDPHASE32015-10-132021-11-112018-10-01
NCT02564497A Study to Compare the Pharmacokinetics of Belatacept Using Active Pharmaceutical Ingredient Manufactured by Process E Relative to Process CCOMPLETEDPHASE12015-10-022017-01-272017-01-27
NCT02534636Safety Study of BMS-986165 in Healthy Subjects and to Treat PsoriasisCOMPLETEDPHASE12015-102016-112016-11
NCT02481830Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung CancerCOMPLETEDPHASE32015-09-142022-08-302018-08-17
NCT02504268Effects of Abatacept in Patients With Early Rheumatoid ArthritisCOMPLETEDPHASE32015-09-032020-03-192017-01-16
NCT02439190CV004-007 Thrombosis Chamber StudyCOMPLETEDPHASE12015-092016-032016-03
NCT02477826An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)COMPLETEDPHASE32015-08-052024-10-252024-10-25
NCT02536469HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid TumorsCOMPLETEDPHASE12015-082016-112016-11
NCT02496078A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b InfectionCOMPLETEDPHASE32015-082017-022016-08
NCT02297139Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating DasatinibCOMPLETEDPHASE22015-07-312022-05-152022-05-15
NCT02472977Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid TumorsTERMINATEDPHASE1, PHASE22015-07-132017-01-272017-01-27
NCT02341625A Study of BMS-986148 in Patients With Select Advanced Solid TumorsTERMINATEDPHASE1, PHASE22015-06-192020-05-072019-02-25
NCT02419417Study of BMS-986158 in Subjects With Select Advanced CancersCOMPLETEDPHASE1, PHASE22015-06-192021-03-172021-03-17
NCT02415400A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the HeartCOMPLETEDPHASE42015-06-042018-11-102018-11-10
NCT03400163A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)COMPLETEDPHASE22015-05-082017-06-192017-01-18
NCT02413372A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)COMPLETEDPHASE22015-05-082017-06-192017-01-18
NCT02456844Study to Investigate the Effect of BMS-986142 on the Pharmacokinetics (PK) of Methotrexate and Probe Substrate Cocktail in Healthy PatientsCOMPLETEDPHASE12015-052015-072015-07
NCT02409368An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLCCOMPLETEDPHASE22015-04-292021-08-272018-03-07
NCT01884337Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement SurgeryCOMPLETEDPHASE42015-03-242018-06-042018-06-04
NCT02388906Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV MelanomaCOMPLETEDPHASE32015-03-162024-10-162018-11-26
NCT02387996A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder CancerCOMPLETEDPHASE22015-03-092021-11-122016-04-15
NCT02320058An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by ItselfCOMPLETEDPHASE22015-03-052020-09-082020-09-08
NCT02272803Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in JapanCOMPLETEDPHASE22015-02-202021-07-212017-02-09
NCT02319031Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated CirrhosisCOMPLETEDPHASE32015-022015-122015-10
NCT02305563An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid LeukemiaTERMINATEDPHASE1, PHASE22015-01-272019-06-042019-06-04
NCT02307656Taste Properties of Atazanavir and CobicistatCOMPLETEDPHASE12014-12-122021-09-092021-09-09
NCT02252263A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple MyelomaCOMPLETEDPHASE12014-12-092017-10-102017-10-10
NCT02279862Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy NaiveCOMPLETEDPHASE22014-12-022016-12-152016-12-15
NCT02323594A Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and AsunaprevirCOMPLETEDPHASE12014-122015-022015-02
NCT02273960Study to Evaluate Safety and Efficacy in Adult Subjects With ITPCOMPLETEDPHASE1, PHASE22014-11-172018-01-222018-01-22
NCT02247349BMS-986012 in Relapsed/Refractory SCLCCOMPLETEDPHASE1, PHASE22014-11-142022-12-222022-12-21
NCT02265744Safety and Efficacy Study of a Biologic to Treat Systemic Lupus ErythematosusCOMPLETEDPHASE22014-11-132017-11-302017-10-26
NCT02286219Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors (Anti HER2 Fcab)COMPLETEDPHASE12014-11-042017-06-082017-06-08
NCT02350114An Observational Study of the Functional Capacity of Heart FailureCOMPLETEDNA2014-112015-072015-05
NCT02153437Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using PacemakersTERMINATEDPHASE12014-10-302016-10-202016-10-20
NCT02231749Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)COMPLETEDPHASE32014-10-162025-03-212017-06-26
NCT02279732Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and CarboplatinCOMPLETEDPHASE32014-10-132018-05-032018-05-03
NCT02156804A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)COMPLETEDPHASE22014-10-072019-01-182019-01-18
NCT02227459Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)COMPLETEDPHASE12014-102016-052016-05
NCT02327273Randomized, Placebo-Controlled, Double-Blind, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-963272 in Healthy SubjectsCOMPLETEDPHASE12014-102015-052015-05
NCT02293629A Single and Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Target Engagement of BMS-986147 in Healthy SubjectsCOMPLETEDPHASE12014-102014-112014-11
NCT00947245Japanese Bridging Study Conducted in the United StatesWITHDRAWNPHASE12014-102015-022015-02
NCT02253992An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's LymphomaTERMINATEDPHASE1, PHASE22014-09-292019-05-242019-05-24
NCT02341638Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy SubjectsCOMPLETEDPHASE12014-092015-092015-09
NCT02257151Study to Evaluate the Safety, Pharmacokinetics and Target Engagement of BMS-986142 in Healthy SubjectsCOMPLETEDPHASE12014-092015-082015-08
NCT02227173A Phase 1 Drug-drug Interaction Study in Healthy VolunteersCOMPLETEDPHASE12014-092014-112014-11
NCT02181738Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)COMPLETEDPHASE22014-08-122022-12-272017-08-31
NCT02208882Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-986120 in Healthy Subjects and the Effects of Co-Administration of Midazolam and BMS-986120COMPLETEDPHASE12014-082015-022015-02
NCT02211469A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male SubjectsCOMPLETEDPHASE12014-082015-072015-07
NCT02175966Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)COMPLETEDPHASE22014-07-282015-12-172015-01-28
NCT02156076A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial FibrillationTERMINATEDPHASE22014-07-252016-06-012016-06-01
NCT02164812Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy SubjectsCOMPLETEDPHASE12014-072015-082015-08
NCT02157506A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart FailureCOMPLETEDPHASE22014-06-302015-07-312015-05-31
NCT02170727A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1COMPLETEDPHASE32014-06-262015-09-092015-06-12
NCT02159352Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy ParticipantsCOMPLETEDPHASE12014-062014-072014-07
NCT02175602Study of Drug Combination on Pharmacokinetics in Healthy VolunteersCOMPLETEDPHASE12014-062014-08
NCT01797848Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve PatientsWITHDRAWNPHASE32014-062016-112016-11
NCT02105636Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)COMPLETEDPHASE32014-05-292021-09-102015-11-06
NCT02079480Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy SubjectsTERMINATEDPHASE12014-052016-042016-04
NCT02097277A Study to Evaluate BMS-986036 in Obese Adults With Type-2 DiabetesCOMPLETEDPHASE22014-04-152016-05-172015-09-22
NCT02066636A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy RegimenCOMPLETEDPHASE32014-04-092021-10-062021-10-06
NCT02110082Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck CancerCOMPLETEDPHASE12014-042016-122016-12
NCT02123654UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis CCOMPLETEDPHASE32014-042015-082015-01
NCT02095860Food Effect of a Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325COMPLETEDPHASE12014-042014-052014-05
NCT02103569Drug Interaction Study of an OCP (Norethindrone (ND) Acetate and Ethinyl Estradiol (EE))With a Combination of Daclatasvir (DCV) Asunaprevir (ASV) and BMS-791325COMPLETEDPHASE12014-042014-072014-07
NCT02084953Study to Determine the Effect of BMS-791325 on the ECG QTcF Interval in Healthy SubjectsCOMPLETEDPHASE12014-042014-052014-05
NCT02104843Drug Interaction Between Daclatasvir/Asunaprevir/BMS-791325 and RosuvastatinCOMPLETEDPHASE12014-042014-052014-05
NCT02108639To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination TabletCOMPLETEDPHASE12014-042014-062014-06
NCT02112110Absolute Bioavailability of BMS-791325COMPLETEDPHASE12014-042014-052014-05
NCT01666704Proof of Concept Study of BMS-823778 to Assess the Effects on AtherosclerosisWITHDRAWNPHASE22014-042016-052015-10
NCT02041533An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)COMPLETEDPHASE32014-03-272022-05-272016-07-01
NCT02038946Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)COMPLETEDPHASE22014-03-262020-12-282017-05-17
NCT02061761A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell MalignanciesCOMPLETEDPHASE1, PHASE22014-03-132022-02-162022-02-16
NCT02060188A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has SpreadCOMPLETEDPHASE22014-03-122024-10-222024-10-22
NCT02159365Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma PatientsCOMPLETEDPHASE22014-03-082018-07-112016-06-30
NCT02038933Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)COMPLETEDPHASE22014-03-052020-10-082016-04-08
NCT02032875Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver TransplantCOMPLETEDPHASE32014-032016-012014-11
NCT02101112Bioavailability of Apixaban Crushed TabletCOMPLETEDPHASE12014-032014-052014-05
NCT02089061Drug Interaction StatinCOMPLETEDPHASE12014-032014-052014-05
NCT02101125Drug Interaction Study With RosuvastatinCOMPLETEDPHASE12014-032014-052014-05
NCT02068053Absorption, Distribution, Metabolism and Excretion (ADME) Study of BMS-986020COMPLETEDPHASE12014-032014-042014-04
NCT01995266Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude DualCOMPLETEDPHASE32014-02-282015-07-312015-07-31
NCT02017717A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma PatientsCOMPLETEDPHASE32014-02-072024-06-212019-06-17
NCT02011945A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid LeukemiaCOMPLETEDPHASE12014-02-072018-12-262018-12-26
NCT02819271A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy VolunteersCOMPLETEDPHASE12014-022014-042014-04
NCT02032888A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.COMPLETEDPHASE32014-022015-012014-10
NCT02074358A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult SubjectsCOMPLETEDPHASE12014-022014-042014-04
NCT02045966Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy SubjectsCOMPLETEDPHASE12014-022014-042014-04
NCT02045693Drug Interaction & Methadone & BuprenorphineCOMPLETEDPHASE12014-022014-042014-04
NCT01850004Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular ResponseCOMPLETEDPHASE22014-01-222021-10-082017-09-20
NCT02032901Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCVCOMPLETEDPHASE32014-012014-122014-09
NCT02017730To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding in Lung Using PET (Positron Emission Tomography) In Healthy VolunteersCOMPLETEDPHASE12014-012015-012015-01
NCT01990859Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma PatientsCOMPLETEDPHASE22013-122015-022014-05
NCT01979939UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic SubjectsCOMPLETEDPHASE32013-122014-112014-08
NCT01973049UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated CirrhosisCOMPLETEDPHASE32013-122014-112014-08
NCT03197779A Short and Long Intravenous Infusion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-962212 in Healthy SubjectsCOMPLETEDPHASE12013-11-182017-01-242016-02-02
NCT01968109An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid TumorsCOMPLETEDPHASE1, PHASE22013-11-052025-02-032024-05-22
NCT01986218Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid TumorsTERMINATEDPHASE12013-112016-032016-03
NCT01146171Japanese Phase 1 Study of BMS-844203 (CT322)WITHDRAWNPHASE12013-112015-012015-01
NCT01928394A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid TumorsCOMPLETEDPHASE1, PHASE22013-10-242024-11-182019-02-05
NCT01884350Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)COMPLETEDPHASE42013-10-152016-01-202016-01-20
NCT01891643PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)TERMINATEDPHASE32013-09-302020-06-252020-06-25
NCT01844518Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)COMPLETEDPHASE32013-08-302023-02-012015-03-12
NCT01927419Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic MelanomaCOMPLETEDPHASE22013-08-232021-02-262014-07-24
NCT01835470Efficacy, Safety, Pharmacokinetics and Immunogenicity Study of Abatacept Administered Intravenously to Treat Active Polyarticular-course Juvenile Idiopathic Arthritis in JapanCOMPLETEDPHASE32013-08-092018-07-302015-11-24
NCT01866930Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIVTERMINATEDPHASE32013-07-112015-08-272015-08-27
NCT01890473Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled SyringeCOMPLETEDPHASE12013-072014-112014-11
NCT01864174Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 DiabetesCOMPLETEDPHASE42013-06-202016-06-012016-06-01
NCT01860976Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic ArthritisCOMPLETEDPHASE32013-06-172020-06-302015-07-14
NCT01844505Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)COMPLETEDPHASE32013-06-112024-04-192016-08-01
NCT01791491Pharmacokinetics, Safety and Tolerability of Single-dose Belatacept in Adolescent Kidney Transplant RecipientsCOMPLETEDPHASE22013-05-092016-12-062016-12-06
NCT01858935A Phase 1, Randomized, Double-Blind, Placebo-Controlled Escalating Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ND-L02-s0201 Injection in Normal Healthy SubjectsCOMPLETEDPHASE12013-052014-022014-02
NCT01836705Effect of SAR302503 on ECG Activity in Patients With Solid TumorsCOMPLETEDPHASE12013-052014-052013-11
NCT00996879Study to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy SubjectsCOMPLETEDPHASE12013-052013-092013-09
NCT01783938Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)COMPLETEDPHASE22013-04-302020-08-122015-04-03
NCT01758198Abatacept Post-marketing Clinical Study in JapanCOMPLETEDPHASE42013-04-112016-12-262016-12-26
NCT01844895Methotrexate-Inadequate Response Autoinjector Device Sub StudyCOMPLETEDPHASE32013-042014-072014-07
NCT01837719Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With CobicistatCOMPLETEDPHASE12013-042013-062013-06
NCT01741545Safety and Efficacy Study in Subjects With Chronic HCV and Underlying HemophiliaCOMPLETEDPHASE32013-03-312015-01-312015-01-31
NCT01820572A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-BasedCOMPLETEDPHASE32013-03-272019-10-242019-10-24
NCT01752985Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney DiseaseTERMINATEDPHASE22013-03-182015-06-302015-06-30
NCT01775631Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins LymphomaCOMPLETEDPHASE12013-032016-082016-08
NCT01795911Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With RibavirinCOMPLETEDPHASE22013-032014-092014-04
NCT01709162Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced MelanomaTERMINATEDPHASE22013-032014-072014-07
NCT01629732Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis CWITHDRAWNPHASE22013-032014-062014-02
NCT01754974Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis CCOMPLETEDPHASE32013-032014-092014-09
NCT01766817Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary FibrosisCOMPLETEDPHASE22013-01-312016-02-292016-02-29
NCT01714817Efficacy and Safety Study of Abatacept to Treat Lupus NephritisTERMINATEDPHASE32013-01-222018-05-302016-11-21
NCT01721772Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic MelanomaCOMPLETEDPHASE32013-01-182021-05-142014-06-24
NCT01707394Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic DisorderCOMPLETEDPHASE12013-01-102020-06-302020-06-30
NCT01718158Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) TherapyCOMPLETEDPHASE32013-012014-102014-10
NCT01766050Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy VolunteersCOMPLETEDPHASE42013-012013-042013-04
NCT01721746A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)COMPLETEDPHASE32012-12-212020-12-292016-02-16
NCT01660906Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to ImatinibCOMPLETEDPHASE42012-122015-102015-10
NCT01750580Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced TumorCOMPLETEDPHASE12012-122015-042015-04
NCT01762462Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic ImpairmentCOMPLETEDPHASE12012-122013-032013-03
NCT01691794Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric PatientsCOMPLETEDPHASE42012-11-302017-02-202014-10-31
NCT01721759Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic RegimensCOMPLETEDPHASE22012-11-162021-04-222014-01-22
NCT01696045Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant MelanomaTERMINATEDPHASE22012-11-122016-07-312016-07-31
NCT01673867Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLCCOMPLETEDPHASE32012-11-022021-12-172015-02-05
NCT01718145A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV SubjectsCOMPLETEDPHASE32012-112014-122013-12
NCT01763190Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal ImpairmentCOMPLETEDPHASE12012-112013-072013-07
NCT01692366Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With SplenomegalyCOMPLETEDPHASE22012-112014-032014-03
NCT01886599Study of the Pharmacokinetics and Safety of Asunaprevir in Patients With Kidney DiseaseCOMPLETEDPHASE12012-112013-022013-02
NCT01651273A Safety Study of BMS-852927 in Subjects With HypercholesterolemiaTERMINATEDPHASE12012-112013-062013-06
NCT01658878An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver CancerCOMPLETEDPHASE1, PHASE22012-10-302024-11-122024-11-12
NCT01642004Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)COMPLETEDPHASE32012-10-162021-08-162014-11-17
NCT01653470Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid TumorsCOMPLETEDPHASE12012-10-122017-05-082017-05-03
NCT01668784Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)COMPLETEDPHASE32012-10-092021-07-192015-05-06
NCT01714739A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid TumorsCOMPLETEDPHASE1, PHASE22012-10-072019-12-132019-12-13
NCT01681212Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced MelanomaCOMPLETEDPHASE22012-102014-052014-05
NCT01621490PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced MelanomaCOMPLETEDPHASE12012-09-272018-10-252017-09-12
NCT01673854Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced MelanomaCOMPLETEDPHASE22012-09-132015-05-122014-07-25
NCT01593254Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to ImatinibCOMPLETEDPHASE22012-09-122022-04-122017-11-08
NCT01830205Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal ImpairmentCOMPLETEDPHASE12012-092013-062013-06
NCT01708889Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal DysfunctionCOMPLETEDPHASE12012-092013-022013-02
NCT01611558Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian CancerCOMPLETEDPHASE22012-08-212019-07-032014-11-03
NCT01592370An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple MyelomaCOMPLETEDPHASE1, PHASE22012-08-022024-07-092020-09-25
NCT01620944Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TCTERMINATEDPHASE32012-07-312013-01-222013-01-22
NCT01628692Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C VirusCOMPLETEDPHASE22012-072013-112013-08
NCT01585987An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line ChemotherapyCOMPLETEDPHASE22012-072015-042014-07
NCT01616524Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3COMPLETEDPHASE32012-072014-092014-06
NCT01602367Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese PatientsTERMINATEDPHASE22012-072012-112012-11
NCT01614756A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic DermatitisCOMPLETEDPHASE12012-072015-042015-04
NCT01605994Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-933043 in Healthy SubjectsCOMPLETEDPHASE12012-072013-122013-12
NCT01471197Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung CancerTERMINATEDPHASE22012-072013-022013-02
NCT01605084Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI BackboneWITHDRAWNPHASE32012-06-302014-08-312014-08-31
NCT01598090Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With TelaprevirCOMPLETEDPHASE32012-06-142015-05-152015-02-04
NCT01629758Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid TumorsCOMPLETEDPHASE12012-062014-122014-12
NCT01585623Drug Interaction Study of SAR302503 in Patients With Solid TumorCOMPLETEDPHASE12012-062013-032013-03
NCT01514864Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF MutationTERMINATEDPHASE22012-05-312014-07-232014-07-23
NCT01632150Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple MyelomaCOMPLETEDPHASE22012-052016-032013-10
NCT01425970Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or RibavirinTERMINATEDPHASE22012-052013-082013-08
NCT01573351Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)COMPLETEDPHASE32012-052013-122013-09
NCT01581203Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)COMPLETEDPHASE32012-052014-092013-10
NCT01587365Single Ascending Dose Safety Study of BMS-962476 in Healthy Subjects and Patients With Elevated Cholesterol on StatinsCOMPLETEDPHASE12012-052013-052013-05
NCT01460160Pediatric Philadelphia Positive Acute Lymphoblastic LeukemiaCOMPLETEDPHASE22012-04-132021-06-012017-05-28
NCT01523171Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With RuxolitinibCOMPLETEDPHASE22012-042014-042014-04
NCT01525212Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected PatientsWITHDRAWNPHASE12012-042013-022013-02
NCT01540461Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)COMPLETEDPHASE12012-032013-112013-11
NCT01515202Japanese Phase 1 Multiple Ascending Dose StudyCOMPLETEDPHASE12012-032012-092012-09
NCT01447394Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis CWITHDRAWNPHASE32012-032014-082014-03
NCT01515189Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg IpilimumabCOMPLETEDPHASE32012-02-172017-08-172016-02-06
NCT01472081Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)COMPLETEDPHASE12012-02-092021-06-032016-02-02
NCT01471210Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's LymphomaCOMPLETEDPHASE12012-022016-042016-04
NCT01492374Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's DiseaseCOMPLETEDPHASE12012-022013-102013-10
NCT01525823Assessment of Blood Glucose Changes in Healthy Volunteers After BMS-754807 Alone or BMS-754807 With MetforminCOMPLETEDPHASE12012-022012-042012-04
NCT01393964Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal FunctionCOMPLETEDPHASE12012-01-062016-07-182014-03-21
NCT01492426Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus InfectionCOMPLETEDPHASE32012-012014-032013-12
NCT01497834A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) PatientsCOMPLETEDPHASE32012-012013-062013-04
NCT01441973Biomarker Study of Elotuzumab in High Risk Smoldering MyelomaCOMPLETEDPHASE22011-12-282017-01-172014-05-30
NCT01454102Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)COMPLETEDPHASE12011-12-162021-07-232016-07-20
NCT01450761Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy AloneCOMPLETEDPHASE32011-12-132017-05-172015-03-19
NCT01471574Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV VirusCOMPLETEDPHASE32011-122014-092014-06
NCT01437787Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With MyelofibrosisCOMPLETEDPHASE32011-122014-062014-06
NCT01466374Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's DiseaseCOMPLETEDPHASE22011-122014-122014-06
NCT01448044Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis CCOMPLETEDPHASE32011-122014-012013-10
NCT01489059Safety Study of IL-21/Ipilimumab Combination in the Treatment of MelanomaCOMPLETEDPHASE12011-122014-062014-06
NCT01478048Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple MyelomaCOMPLETEDPHASE22011-11-302017-04-212014-05-30
NCT01455090Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available MedicationsCOMPLETEDPHASE22011-11-302015-07-312014-03-31
NCT01400451Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)TERMINATEDPHASE12011-112013-122013-04
NCT01413906Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects With Solid TumorsCOMPLETEDPHASE12011-112012-112012-11
NCT01452334Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic MalignancyWITHDRAWNPHASE12011-112014-112014-11
NCT01455103Phase 1 Biomarker Study of Anti-PDL-1 in Advanced MelanomaWITHDRAWNPHASE12011-112013-112013-11
NCT02034591Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy SubjectsCOMPLETEDPHASE12011-102011-112011-11
NCT01420783Study With SAR302503 in Patients With Polycythemia Vera or Essential ThrombocythemiaCOMPLETEDPHASE22011-102014-052012-11
NCT01332227Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected PatientsCOMPLETEDPHASE42011-102014-022013-09
NCT01439204Pharmacokinetic Study to Compare the Blood Levels of Abatacept Manufactured at Lonza Biologics to the Blood Levels of Abatacept Manufactured at the Devens, Massachusetts (MA) Facility of Bristol-Myers SquibbCOMPLETEDPHASE12011-102012-022012-02
NCT01471717Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy SubjectsCOMPLETEDPHASE1, PHASE22011-102011-112011-11
NCT01471704Study Investigating the Pharmacokinetic Interaction Between INX-08189 and Verapamil HCL ER in Healthy VolunteersCOMPLETEDPHASE1, PHASE22011-102011-112011-11
NCT01363817Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic LymphomaCOMPLETEDPHASE12011-09-282018-02-072018-02-07
NCT01358721Phase I Biomarker Study (BMS-936558)COMPLETEDPHASE12011-09-232019-05-222014-12-01
NCT01357655Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)TERMINATEDPHASE22011-092016-012016-01
NCT01445795Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve SubjectsCOMPLETEDPHASE1, PHASE22011-092012-052012-05
NCT01428063Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus TrialsCOMPLETEDPHASE22011-092014-122014-09
NCT01389323BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis CCOMPLETEDPHASE32011-092014-012013-09
NCT01404585Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid ArthritisCOMPLETEDPHASE22011-092013-022013-02
NCT01359657Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple MyelomaCOMPLETEDPHASE12011-092016-032016-03
NCT01396252Japanese Phase 1 Multiple Ascending Dose (MAD) StudyCOMPLETEDPHASE12011-092012-052012-05
NCT01335399Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple MyelomaCOMPLETEDPHASE32011-08-042021-09-032019-10-01
NCT01420770Phase 2 Study of SAR302503 in Patients With MyelofibrosisCOMPLETEDPHASE22011-082014-042014-04
NCT01361555Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major DepressionTERMINATEDPHASE22011-082013-102013-10
NCT01404572Taste Assessment Study of 2 Atazanavir Powder Formulations in Healthy SubjectsCOMPLETEDPHASE12011-082011-092011-09
NCT01195727Multiple-Dose Study Apixaban in Pediatric Subjects With an Indwelling Central Venous CatheterTERMINATEDPHASE12011-07-262012-07-162012-06-14
NCT02034578Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy SubjectsCOMPLETEDPHASE12011-072011-082011-08
NCT01369095Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major DepressionCOMPLETEDPHASE22011-072013-052013-05
NCT01392703Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed FormulationsCOMPLETEDPHASE12011-072011-092011-09
NCT01239797Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple MyelomaCOMPLETEDPHASE32011-06-202021-04-212014-09-02
NCT01340586Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on HemodialysisCOMPLETEDPHASE12011-062011-092011-09
NCT01359644Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of CareCOMPLETEDPHASE22011-062013-102013-01
NCT01354431BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)COMPLETEDPHASE22011-05-312021-04-152013-05-15
NCT01335698Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric PatientsCOMPLETEDPHASE32011-05-272018-01-222014-09-10
NCT01356914Pacemaker Holter Assessment of the Effect of BMS-914392 on Atrial Fibrillation BurdenCOMPLETEDPHASE22011-052012-062012-06
NCT01236352Multiple Ascending Dose of BMS-911543TERMINATEDPHASE1, PHASE22011-04-072015-11-192015-11-19
NCT01309945Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major DepressionCOMPLETEDPHASE22011-042013-012013-01
NCT01292655Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid TumorsCOMPLETEDPHASE12011-03-032017-06-222017-06-22
NCT01314222Diabetic Peripheral Neuropathic Pain (DPNP)COMPLETEDPHASE22011-032012-072012-03
NCT01305538Crossover Post-herpetic Neuralgia (PHN)COMPLETEDPHASE22011-032012-062012-02
NCT01309932Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With RibavirinCOMPLETEDPHASE22011-032014-092014-07
NCT01294410Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative ColitisCOMPLETEDPHASE22011-032014-122012-12
NCT01227668Phase IV Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic DisorderCOMPLETEDPHASE42011-032012-062012-06
NCT01489046Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naiveTERMINATEDPHASE22011-022014-072013-03
NCT01137578Pediatric Catheter-related Thrombosis Imaging StudyCOMPLETEDNA2011-022013-052013-05
NCT01232127Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV InfectionCOMPLETEDPHASE42011-022011-062011-06
NCT01290575Multiple Ascending Dose Study of BMS-820132 in Patients With Type 2 DiabetesCOMPLETEDPHASE12011-022011-112011-11
NCT01285609Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and CarboplatinCOMPLETEDPHASE32011-01-162017-08-222015-06-09
NCT01241292Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose DexamethasoneCOMPLETEDPHASE12011-01-142017-01-162014-02-14
NCT01218477Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)COMPLETEDPHASE1, PHASE22011-012013-042013-04
NCT01245556Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced MelanomaCOMPLETEDPHASE12011-012012-112012-11
NCT01225172Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase InhibitorsTERMINATEDPHASE22010-12-312014-11-302014-11-30
NCT01142726Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid ArthritisCOMPLETEDPHASE32010-122014-102013-09
NCT01257204Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus InfectionCOMPLETEDPHASE22010-122012-092012-05
NCT01204762Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e AntigenCOMPLETEDPHASE22010-112013-122013-12
NCT00803374Combination of Anti-CD137 & Ipilimumab in Patients With MelanomaWITHDRAWNPHASE12010-112013-012012-07
NCT01240980Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) & Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 & 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B)COMPLETEDPHASE12010-112012-012012-01
NCT01099579PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV)COMPLETEDPHASE32010-10-132017-09-112012-10-04
NCT01193361Ph IIA Study (SOC +/- NS5B)COMPLETEDPHASE22010-102012-112011-06
NCT01250366Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve SubjectsCOMPLETEDPHASE12010-102011-062011-03
NCT01221636Pharmacokinetic Study to Compare the Blood Levels of Low vs High Metal Manufacture of AbataceptWITHDRAWNPHASE12010-102011-022011-02
NCT01165216Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung CancerCOMPLETEDPHASE12010-092013-062013-06
NCT01211808Effect of Diltiazem on Pharmacokinetics of BMS-914392COMPLETEDPHASE12010-092010-102010-10
NCT01211821Effect of BMS-914392 on Pharmacokinetics of MetoprololCOMPLETEDPHASE12010-092010-112010-11
NCT01167244Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior ResponseCOMPLETEDPHASE22010-082011-042011-04
NCT01170962Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior TreatmentCOMPLETEDPHASE22010-082012-122012-06
NCT01120457First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell CancersCOMPLETEDPHASE12010-082014-112014-11
NCT01002079Drug-Drug Interaction Study With RifampinCOMPLETEDPHASE12010-082010-102010-10
NCT01057810Phase 3 Study of Immunotherapy to Treat Advanced Prostate CancerCOMPLETEDPHASE32010-072015-072015-04
NCT01086267Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal CancerCOMPLETEDPHASE1, PHASE22010-072011-082011-08
NCT01111955Safety Study of BMS-823778 in Subjects With Type 2 DiabetesCOMPLETEDPHASE22010-072011-012011-01
NCT01125189Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve PatientsCOMPLETEDPHASE22010-072012-082012-04
NCT01142700A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype IWITHDRAWNPHASE22010-072010-122010-12
NCT01079806A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus InfectionCOMPLETEDPHASE32010-06-302018-03-312013-03-31
NCT01068704Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast CancerCOMPLETEDPHASE22010-062010-122010-12
NCT01112423Safety Study of BMS-823778 in Subjects With HypercholesterolemiaCOMPLETEDPHASE22010-062010-122010-12
NCT01152372Experimental Study to Validate the Modified Glucose Disposal TestCOMPLETEDPHASE12010-062010-112010-11
NCT01108705Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib TreatmentTERMINATEDPHASE32010-052013-102013-10
NCT01046422Safety Study of BMS-770767 in Subjects With Type 2 DiabetesCOMPLETEDPHASE22010-052011-012011-01
NCT01063036Efficacy and Safety Study of Entecavir Plus Tenofovir in Patients With Chronic Hepatitis B Who Failed Previous TreatmentCOMPLETEDPHASE32010-052014-022012-11
NCT01159808A Study of the Safety and Pharmacokinetics of Single Ascending Oral Doses of INX-08189 in Healthy SubjectsCOMPLETEDPHASE12010-052010-102010-08
NCT01058083Safety Study of BMS-770767 in Subjects With HypercholesterolemiaCOMPLETEDPHASE22010-052011-032011-03
NCT01124344Safety and Pharmacology Study of BMS-866949TERMINATEDPHASE12010-052011-112011-11
NCT01105429Single Ascending Dose Study of BMS-820132 in Patients With Type 2 DiabetesCOMPLETEDPHASE12010-052010-102010-10
NCT01051414An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) SubjectCOMPLETEDPHASE22010-042012-052011-09
NCT01096043A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart FailureCOMPLETEDPHASE22010-042012-022012-02
NCT01079819Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163COMPLETEDPHASE12010-042010-122010-12
NCT01082562Safety Study of BMS-844421 for Treatment of HypercholesterolemiaTERMINATEDPHASE12010-042010-072010-07
NCT01097668ATX-MS-1467 in Patients With Relapsing Forms of Multiple SclerosisCOMPLETEDPHASE12010-032013-072013-07
NCT01057030Multiple Dose Japanese Bridging StudyCOMPLETEDPHASE12010-032010-062010-06
NCT02034565Phase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy SubjectsCOMPLETEDPHASE12010-022010-032010-03
NCT01030432Study of BMS-650032 With Peginterferon Alfa-2a Plus RibavirinCOMPLETEDPHASE22010-022012-102012-10
NCT01046864Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)COMPLETEDPHASE12010-022014-062014-06
NCT00927875A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung CancerCOMPLETEDPHASE12010-022012-092012-09
NCT01049165Single Ascending Dose (BMS-813160) StudyCOMPLETEDPHASE12010-022010-112010-11
NCT01018745Multiple Ascending Dose Study of BMS-907351 (XL184) in Patients With Solid Tumors in JapanCOMPLETEDPHASE12010-012010-072010-07
NCT01063023Drug Interaction Oral Contraceptive Pill (OCP)COMPLETEDPHASE12010-012010-062010-06
NCT01042314Drug-Drug Interaction Study With Aricept® (Donepezil)COMPLETEDPHASE12010-012010-042010-04
NCT01039194Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)COMPLETEDPHASE12010-012010-042010-04
NCT01024231Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant MelanomaCOMPLETEDPHASE12009-12-142019-04-012014-02-04
NCT01012895Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of CareCOMPLETEDPHASE22009-122014-022012-10
NCT01016912Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese PatientsCOMPLETEDPHASE22009-122010-092010-09
NCT01017575Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)COMPLETEDPHASE22009-122011-102011-10
NCT01001832Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese PatientsCOMPLETEDPHASE2, PHASE32009-122012-102011-02
NCT01019070Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032COMPLETEDPHASE12009-122011-082011-08
NCT00986778Entecavir Plus Adefovir in Lamivudine-Resistant PatientsWITHDRAWNPHASE42009-122014-062012-12
NCT00778622Body Weight Effects on Glucophage's Efficacy in Chinese Diagnosed T2DM PatientsCOMPLETEDPHASE42009-112011-032011-03
NCT00909402A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal AdenocarcinomasCOMPLETEDPHASE12009-112012-112012-11
NCT01173120Methotrexate - Inadequate Response Device Sub-StudyCOMPLETEDPHASE32009-112010-072010-02
NCT00979368Safety Study of BMS-816336 in Healthy Male SubjectsCOMPLETEDPHASE12009-112010-022010-02
NCT00851045Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal CancerCOMPLETEDPHASE22009-102011-102011-09
NCT00983957Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female SubjectsCOMPLETEDPHASE12009-102010-022010-02
NCT00929864Abatacept Versus Adalimumab Head-to-HeadCOMPLETEDPHASE32009-102012-112011-10
NCT00908024Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid TumorsTERMINATEDPHASE1, PHASE22009-102012-122012-12
NCT00948389Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)TERMINATEDPHASE1, PHASE22009-102011-052011-05
NCT00971308Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C VirusCOMPLETEDPHASE12009-102010-082010-08
NCT00833482Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy ParticipantsCOMPLETEDPHASE12009-092011-022010-07
NCT00898716Multiple Ascending Dose Study of BMS-754807 in Patients With Solid Tumors in JapanCOMPLETEDPHASE12009-092011-072011-07
NCT00979316Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy SubjectsCOMPLETEDPHASE12009-092010-022010-02
NCT00909766Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese SubjectsCOMPLETEDPHASE1, PHASE22009-082011-062011-06
NCT00920907Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced MelanomaCOMPLETEDPHASE12009-082012-102010-04
NCT00732186Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid LeukemiaWITHDRAWNPHASE12009-082011-022011-02
NCT00908752Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCCCOMPLETEDPHASE32009-07-202018-01-262012-09-28
NCT00944905Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)COMPLETEDPHASE12009-072012-112012-11
NCT00788333Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast CancerCOMPLETEDPHASE1, PHASE22009-072011-112011-11
NCT00884546Multiple Ascending Dose (MAD) Combination in Subjects With Multiple MyelomaCOMPLETEDPHASE12009-072012-032012-03
NCT00935506Ex Vivo Human Thrombosis Chamber StudyCOMPLETEDPHASE12009-072009-102009-10
NCT00949767Safety, Pharmacokinetics and Pharmacodynamics Study of BMS-866949 in Healthy SubjectsCOMPLETEDPHASE12009-072010-032010-03
NCT01092325Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart FailureCOMPLETEDPHASE1, PHASE22009-062010-052010-05
NCT00874770Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)COMPLETEDPHASE22009-062011-012009-11
NCT00850577Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung CancerTERMINATEDPHASE22009-062013-082013-08
NCT00886782A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid TumorsTERMINATEDPHASE1, PHASE22009-05-312010-08-042010-08-04
NCT00858871First Line Hepato Cellular Carcinoma (HCC)COMPLETEDPHASE32009-052013-092012-06
NCT00861614Study of Immunotherapy to Treat Advanced Prostate CancerCOMPLETEDPHASE32009-052015-082012-11
NCT00900783A Study of FV-100 Versus Valacyclovir in Patients With Herpes ZosterCOMPLETEDPHASE22009-052010-122010-11
NCT00890890A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's DiseaseTERMINATEDPHASE22009-052013-072013-07
NCT00872976Study of Dasatinib and Bendamustine in Chronic Lymphocytic LeukemiaWITHDRAWNPHASE12009-052011-122011-12
NCT00892840Multiple-Ascending Dose StudyCOMPLETEDPHASE12009-052010-112010-11
NCT00904059Drug-Drug Interaction Study in Healthy SubjectsCOMPLETEDPHASE12009-052009-072009-07
NCT00730652Study of MDX-1411 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell LymphomaWITHDRAWNPHASE12009-052013-032012-12
NCT00878020Safety Study to Evaluate BMS-830216 in Healthy SubjectsCOMPLETEDPHASE12009-052009-092009-09
NCT00901498Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's DiseaseCOMPLETEDPHASE12009-052009-072009-07
NCT00793897Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid TumorsCOMPLETEDPHASE12009-042012-062012-06
NCT00860275Drug-Drug Interaction (DDI) w/Ketoconazole or FluconazoleCOMPLETEDPHASE12009-042009-062009-06
NCT00777036A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to ImatinibCOMPLETEDPHASE22009-03-202025-01-272016-09-01
NCT00831441Phase III Acute Coronary SyndromeTERMINATEDPHASE32009-032011-032011-03
NCT00859053Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic ImpairmentCOMPLETEDPHASE12009-032009-092009-09
NCT00743938A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLCCOMPLETEDPHASE22009-032012-062010-08
NCT00838890A Study of BMS-863233 in Patients With Hematologic CancerTERMINATEDPHASE1, PHASE22009-032010-012010-01
NCT00798252Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced CancersCOMPLETEDPHASE12009-032015-052015-05
NCT00677313An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With LipodystrophyCOMPLETEDNA2009-032015-012015-01
NCT00847782An Experimental Medicine Study to Evaluate Serum Biomarkers of Lipid MetabolismCOMPLETEDNA2009-032009-092009-09
NCT00825955Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib TreatmentCOMPLETEDPHASE32009-02-172017-08-252011-11-15
NCT00729664Multiple Ascending Dose (MDX1105-01)COMPLETEDPHASE12009-022015-072015-07
NCT00699790Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin ResistanceCOMPLETEDPHASE22009-022009-122009-12
NCT00810147A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's DiseaseCOMPLETEDPHASE22009-022010-062010-06
NCT00796991Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, DacarbazineCOMPLETEDPHASE12009-022012-102009-11
NCT00767520Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast CancerCOMPLETEDPHASE22009-022012-122011-03
NCT00836602Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-779788 in Healthy SubjectsCOMPLETEDPHASE12009-022009-072009-07
NCT00764309Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary FibrosisCOMPLETEDPHASE1, PHASE22009-012011-042010-06
NCT00792558Ascending Multiple-Dose Study of BMS-817378 in Subjects With Advanced CancersWITHDRAWNPHASE12009-012010-112010-11
NCT00570752Efficacy Study of p38 Kinase Inhibitor to Treat Patients With AtherosclerosisCOMPLETEDPHASE22008-122010-122010-11
NCT00767325A Rheumatoid Arthritis Study to Assess Early Response to Abatacept+MTX as Defined by Improvement of Synovitis Measures by Power Doppler UltrasonographyCOMPLETEDPHASE32008-122011-102011-10
NCT00722358A Multiple Ascending Dose Study of BMS-650032 in HCV Infected SubjectsCOMPLETEDPHASE22008-122009-122009-12
NCT03198013A Study of Pharmacokinetics (PK) and Pharmacodynamics (PD) in Relation to Prednisolone in Healthy MalesCOMPLETEDPHASE12008-11-112009-05-182009-05-18
NCT00768989Phase IIB Pilot of Atazanavir + RaltegravirTERMINATEDPHASE22008-112010-052010-01
NCT00730639A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent MalignanciesCOMPLETEDPHASE12008-10-302020-12-222013-02-04
NCT00744497Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate CancerCOMPLETEDPHASE32008-102015-072012-08
NCT00768911CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma MultiformeUNKNOWNPHASE12008-102011-062010-10
NCT00703469A Study of MDX-1106 to Treat Patients With Hepatitis C InfectionCOMPLETEDPHASE12008-102009-102009-10
NCT00828646Safety Study of Multiple-dose of Gamma-secretase Inhibitor in Healthy Male Japanese and Healthy Elderly JapaneseCOMPLETEDPHASE12008-102009-072009-07
NCT00754325Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase InhibitorCOMPLETEDPHASE22008-092014-012011-11
NCT00696072Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or MetastaticCOMPLETEDPHASE22008-082014-062014-06
NCT00705367Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kgCOMPLETEDPHASE12008-082011-072009-01
NCT00593944Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL)COMPLETEDPHASE12008-082010-052010-05
NCT00605384A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B InfectionTERMINATEDPHASE32008-082009-022009-02
NCT00707590Safety Study to Evaluate BMS-767778 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus (T2DM)TERMINATEDPHASE12008-082008-112008-11
NCT00726726Drug Interaction Study With a Potential Alzheimer's Disease CompoundCOMPLETEDPHASE12008-082008-102008-10
NCT00724334A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With MyelofibrosisCOMPLETEDPHASE1, PHASE22008-072014-052014-05
NCT00683423BMS-741672 for Diabetic Neuropathic PainCOMPLETEDPHASE22008-072009-022009-01
NCT00670189A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic CancerCOMPLETEDPHASE12008-072014-052014-04
NCT00623766Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain MetastasesCOMPLETEDPHASE22008-072012-102009-09
NCT00643201Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary EmbolismCOMPLETEDPHASE32008-072013-032013-03
NCT00718887Suboptimal Responders to Adefovir Switching to EntecavirCOMPLETEDPHASE42008-072011-012009-12
NCT00964912Single Dose Study of BMS-820836COMPLETEDPHASE12008-072009-042009-04
NCT00644488A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate CancerCOMPLETEDPHASE12008-072009-032009-03
NCT00636168Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III MelanomaCOMPLETEDPHASE32008-06-302018-11-262013-07-26
NCT00633789Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor TypesCOMPLETEDPHASE22008-062012-122012-02
NCT00594984Phase I/II Combination With Irinotecan- ErbituxCOMPLETEDPHASE1, PHASE22008-052012-122012-12
NCT00664625A Single Ascending Dose Study of BMS-791325 in HCV Infected SubjectsCOMPLETEDPHASE1, PHASE22008-052009-062009-06
NCT00663208A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected SubjectsCOMPLETEDPHASE22008-052009-062009-06
NCT00663702Phase IIIB Switching From Intravenous to Subcutaneous StudyCOMPLETEDPHASE32008-052012-012009-12
NCT00560391Dasatinib in Combination With Revlimid (and Dexamethasone)COMPLETEDPHASE12008-052012-112011-10
NCT00633893Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary EmbolismCOMPLETEDPHASE32008-052012-082012-08
NCT00651508Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)COMPLETEDPHASE22008-042008-102008-10
NCT00780000Clinical Trial of Intravenous Alvespimycin in Patients With Her2 Positive Breast CancerTERMINATEDPHASE22008-042008-062008-06
NCT00656890A Study of MDX-1100 in Subjects With Active Ulcerative ColitisCOMPLETEDPHASE22008-042009-092009-09
NCT00569036Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid TumorsCOMPLETEDPHASE12008-042013-042013-04
NCT00656734Study of MDX-1411 Given Every 14 Days With Pre-medications to Subjects With Clear Cell Kidney Cancer.COMPLETEDPHASE12008-042010-062010-06
NCT00646776Drug Interaction StudyCOMPLETEDPHASE12008-042008-082008-08
NCT00655746The Effect of Omeprazole on the Pharmacokinetics of Dasatinib in Healthy SubjectsCOMPLETEDPHASE12008-042008-052008-05
NCT03196557A Study to Assess the Pharmacodynamics (PD) of Prednisoline in Healthy Male SubjectCOMPLETEDPHASE12008-03-312008-05-052008-05-05
NCT00605735PoC in Rheumatoid Arthritis With MethotrexateCOMPLETEDPHASE22008-032009-092009-08
NCT00612664Phase II, 2nd Line Melanoma - RAND MonotherapyCOMPLETEDPHASE22008-032009-102009-10
NCT00578448Belatacept Pharmacokinetic Trial in Renal TransplantationCOMPLETEDPHASE22008-032012-092009-03
NCT00410202Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant VirusCOMPLETEDPHASE32008-032012-072011-01
NCT00971841Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal CancerCOMPLETEDPHASE22008-032012-042012-04
NCT00605618Multiple Ascending Dose Study of BMS-777607 in Subjects With Advanced or Metastatic Solid TumorsCOMPLETEDPHASE1, PHASE22008-032009-032009-03
NCT00527735Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)COMPLETEDPHASE22008-022011-122009-10
NCT00639834Study of the Safety of MDX-1342 in Combination With Methotrexate in Patients With Rheumatoid ArthritisCOMPLETEDPHASE12008-022010-062010-06
NCT00634452Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's LymphomaCOMPLETEDPHASE12008-022010-012010-01
NCT00560352Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple MyelomaTERMINATEDPHASE12008-022011-022011-02
NCT00546780A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First RelapseCOMPLETEDPHASE32008-022010-032010-03
NCT01017367Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (RA)COMPLETEDPHASE22008-022009-052009-01
NCT00559585Methotrexate-Inadequate Response StudyCOMPLETEDPHASE32008-012014-092009-11
NCT00546247A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1)TERMINATEDPHASE1, PHASE22008-012010-032010-03
NCT00555321Belatacept in Liver Transplant RecipientsTERMINATEDPHASE22008-012011-062010-03
NCT00559247A Single Ascending Dose Study of BMS-650032 in HCV Infected SubjectsCOMPLETEDPHASE1, PHASE22008-012008-072008-07
NCT00461110A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)TERMINATEDPHASE12008-012009-042009-04
NCT00578916Pharmacokinetics and Metabolism of Radiolabeled BMS-690514 in Healthy Male SubjectsCOMPLETEDPHASE12008-012008-012008-01
NCT00569803Subcutaneous Pharmacokinetics of BelataceptCOMPLETEDPHASE12007-122008-082008-08
NCT00550017A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2)TERMINATEDPHASE1, PHASE22007-122010-032010-03
NCT00547521Phase IIIB Subcutaneous Abatacept Monotherapy StudyCOMPLETEDPHASE32007-122014-022008-12
NCT00529763Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) SubjectsCOMPLETEDPHASE22007-11-172022-04-202009-06-17
NCT00546715A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected SubjectsCOMPLETEDPHASE1, PHASE22007-112008-052008-05
NCT00533897Phase IIIB Subcutaneous Missed Dose StudyCOMPLETEDPHASE32007-112014-022008-12
NCT00508157A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic SyndromeTERMINATEDPHASE42007-112009-032009-03
NCT00534313Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic ArthritisTERMINATEDPHASE22007-112011-052008-12
NCT00516451Phase I Study of BMS-690514 in Japanese Patients With Solid TumorsCOMPLETEDPHASE12007-112008-072008-07
NCT00455533Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast CancerCOMPLETEDPHASE22007-102009-122009-12
NCT00982488Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaCOMPLETEDPHASE22007-102014-122014-12
NCT00420186A Phase I Study of BMS-690514 in Combination With Paclitaxel and CarboplatinCOMPLETEDPHASE12007-102012-022012-02
NCT00562419CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With IrinotecanUNKNOWNPHASE22007-102011-122011-06
NCT00493779A Study to Evaluate the Discontinuation Effect of Clopidogrel After Drug Eluting Stent Implantation in Non-diabetic PatientsCOMPLETEDPHASE42007-102008-062008-06
NCT00390936A Study of BMS-582664 in Patients With Advanced or Metastatic Solid TumorsCOMPLETEDPHASE12007-102010-032010-03
NCT00481247A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid LeukemiaCOMPLETEDPHASE32007-092015-122009-12
NCT00479583Combination Trial of BMS-690514 in Combination With FOLFIRI and FOLFOXCOMPLETEDPHASE12007-092010-042010-04
NCT00351325A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid MalignanciesTERMINATEDPHASE12007-092009-032009-03
NCT00435669A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)COMPLETEDPHASE12007-092008-062008-06
NCT00534807A Study of the Interaction of Rifampin and Vinflunine in Subjects With Advanced CancerWITHDRAWNPHASE12007-092008-112008-11
NCT00496769A Phase III Study of Apixaban in Patients With Atrial FibrillationCOMPLETEDPHASE32007-08-312017-05-252010-11-30
NCT00514371A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple MyelomaCOMPLETEDPHASE2, PHASE32007-082009-022009-02
NCT00399906A Study of BMS-582949 in Patients With Moderate to Severe Plaque PsoriasisCOMPLETEDPHASE22007-082009-042009-01
NCT00508287Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 DiabetesCOMPLETEDPHASE12007-082007-112007-11
NCT00518297DDI HV (ATV - Merck)COMPLETEDPHASE12007-082007-122007-12
NCT00481325Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety DisorderCOMPLETEDPHASE2, PHASE32007-072008-032008-03
NCT00455013A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney TransplantationCOMPLETEDPHASE22007-072012-082008-10
NCT00439270Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate CancerCOMPLETEDPHASE1, PHASE22007-072013-012012-02
NCT00437424A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver DysfunctionCOMPLETEDPHASE12007-072010-062010-06
NCT00423891A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-InfectionCOMPLETEDPHASE1, PHASE22007-06-302017-09-042013-08-31
NCT02262533Phase 1 Drug Interaction Study of Apixaban and Atenolol in Healthy SubjectsCOMPLETEDPHASE12007-062007-062007-06
NCT00452673Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast CancerCOMPLETEDPHASE12007-062012-102012-10
NCT00430677Efficacy and Safety Study of Abatacept to Treat Lupus NephritisTERMINATEDPHASE2, PHASE32007-062011-082010-09
NCT00452530Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement SurgeryCOMPLETEDPHASE32007-062009-012009-01
NCT00457002Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical IllnessCOMPLETEDPHASE32007-062011-052011-05
NCT01454115Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163COMPLETEDPHASE12007-062009-032009-03
NCT00420199A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to MethotrexateCOMPLETEDPHASE32007-052010-052009-08
NCT00482703A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid LeukemiaCOMPLETEDPHASE1, PHASE22007-052009-052009-05
NCT00409838A Phase III Study of Abatacept in Patients With Rheumatoid Arthritis and an Inadequate Response to MethotrexateCOMPLETEDPHASE32007-042011-122008-07
NCT00410072Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis BCOMPLETEDPHASE32007-042010-102010-10
NCT00395018Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus InfectionCOMPLETEDPHASE32007-042011-032011-03
NCT00989235Substudy - Low Dose of Abatacept in Subjects With Rheumatoid ArthritisCOMPLETEDPHASE32007-042009-102009-10
NCT00362466A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib TherapyTERMINATEDPHASE32007-042008-062008-06
NCT00423319Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)COMPLETEDPHASE32007-032009-092009-09
NCT00362713Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical ResectionCOMPLETEDPHASE12007-032009-102009-10
NCT00359476A Study of Vinflunine in Patients With Gastric CancerTERMINATEDPHASE2, PHASE32007-032007-112007-10
NCT00393484A Study in Korea of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B InfectionCOMPLETEDPHASE42007-022013-092009-01
NCT00364793Safety, Tolerability and Pharmacokinetics of Efavirenz in HIV-Infected ChildrenCOMPLETEDPHASE1, PHASE22007-022013-072011-12
NCT00397566A Multiple Ascending Dose Study of BMS-707035 in HIV-1 Infected SubjectsWITHDRAWNPHASE22007-022007-02
NCT00402168A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without CorticosteroidsCOMPLETEDPHASE22007-012013-062009-06
NCT00389155First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based TherapyCOMPLETEDPHASE2, PHASE32007-012008-012008-01
NCT00385580Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate CancerCOMPLETEDPHASE22007-012010-102008-12
NCT00339144Study of Dasatinib (BMS-354825) in Patients With Solid TumorsCOMPLETEDPHASE12007-012008-092008-09
NCT00355238A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular CancerCOMPLETEDPHASE22006-12-312010-04-302010-04-30
NCT00412984Apixaban for the Prevention of Stroke in Subjects With Atrial FibrillationCOMPLETEDPHASE32006-12-312011-05-252011-05-25
NCT00410410A Study of Abatacept in Patients With Active Ulcerative ColitisCOMPLETEDPHASE32006-122009-112009-06
NCT00484289A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid ArthritisCOMPLETEDPHASE32006-122010-122010-12
NCT00349518Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALLWITHDRAWNPHASE2, PHASE32006-122007-01
NCT00371345Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast CancerCOMPLETEDPHASE22006-122009-052009-03
NCT00399685Drug Interaction - Oral ContraceptiveCOMPLETEDPHASE12006-122007-082007-08
NCT00371254A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast CancerCOMPLETEDPHASE22006-122008-092008-09
NCT00406653A Study of Abatacept in Patients With Active Crohn's DiseaseTERMINATEDPHASE32006-122009-112009-11
NCT00384904Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected PatientsCOMPLETEDPHASE42006-122007-122007-12
NCT00399438A Study of BMS-562086 in Patients With Irritable Bowel SyndromeCOMPLETEDPHASE22006-122008-012007-10
NCT00332748A Phase I Study of BMS-275183 (Oral Taxane) Given on a Daily Schedule in Combination With Esomeprazole (Nexium) in Patients With Advanced CancerTERMINATEDPHASE12006-122007-12
NCT00371683Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement SurgeryCOMPLETEDPHASE32006-112008-052008-05
NCT00371150Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) InfectionCOMPLETEDPHASE42006-112011-032011-03
NCT00388609Multiple-dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BMS-646256 in Obese SubjectsTERMINATEDPHASE22006-112009-042007-09
NCT00393328Bioequivalence Study of Atazanavir 300 mg CapsuleCOMPLETEDPHASE12006-112006-122006-12
NCT00362726Drug Interaction Study With Atazanavir Administered With and Without Ritonavir and a Cytochrome P450 Substrate RosiglitazoneCOMPLETEDPHASE12006-092006-112006-11
NCT00971867Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck CancerCOMPLETEDPHASE22006-08-042008-11-262008-11-26
NCT00362830A Study of the Alternative Administration of Ixabepilone and VinflunineCOMPLETEDPHASE12006-082007-092007-09
NCT00441337A Study of MDX-1106 in Patients With Selected Refractory or Relapsed MalignanciesCOMPLETEDPHASE12006-082009-112009-11
NCT00324155Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV MelanomaCOMPLETEDPHASE32006-082013-102011-01
NCT00320190Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to ImatinibTERMINATEDPHASE22006-082010-012010-01
NCT00324077Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic PhaseWITHDRAWNPHASE12006-082007-02
NCT00329004A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid TumorsCOMPLETEDPHASE12006-082009-072009-07
NCT00374179CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's LymphomaCOMPLETEDPHASE12006-082009-022008-11
NCT00779428Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating TanespimycinCOMPLETEDPHASE22006-072013-072013-03
NCT00357604Atazanavir and Ritonavir (ATV/RTV) and an Oral Contraceptive in Healthy FemalesCOMPLETEDPHASE12006-072006-112006-11
NCT00357188Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz (ATV/RTV + EFV) in Healthy SubjectsCOMPLETEDPHASE12006-072006-092006-09
NCT00352560Electrophysiological Effects of Irbesartan in Patients With Paroxysmal Atrial Fibrillation (AF)COMPLETEDPHASE32006-072007-062007-06
NCT00359450Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)TERMINATEDPHASE22006-072007-03
NCT00320255A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) CancerCOMPLETEDPHASE22006-062009-012009-01
NCT00326716Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant WomenCOMPLETEDPHASE12006-062009-082009-01
NCT00357721Atazanavir Twice DailyCOMPLETEDPHASE12006-062006-092006-09
NCT00345748A Study of Abatacept in Japanese Patients With Active Rheumatoid Arthritis While Receiving MethotrexateCOMPLETEDPHASE22006-062007-112007-11
NCT00337467Phase IIIb Study to Evaluate the Effectiveness and Safety of Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in Human Immunodeficiency Virus (HIV)-Infected Subjects Evidencing Virologic SuppressionCOMPLETEDPHASE32006-062009-052008-05
NCT00344552Phase II Study of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal CancerCOMPLETEDPHASE22006-062008-032008-03
NCT00357240Drug Interaction Study With Proton Pump InhibitorCOMPLETEDPHASE12006-062006-082006-08
NCT00162123A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab StudiesCOMPLETEDPHASE22006-052014-042012-09
NCT00313300Safety Study of Apixaban in Recent Acute Coronary SyndromeCOMPLETEDPHASE22006-052008-052008-05
NCT00357461Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV MelanomaWITHDRAWNPHASE22006-05
NCT00326586A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate CancerCOMPLETEDPHASE12006-052009-032009-03
NCT00289627A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV MelanomaCOMPLETEDPHASE22006-042007-072007-07
NCT00344045Study to Evaluate The Analgesic Efficacy and Safety of Intravenous Paracetamol in Subjects With Postoperative Pain After Total Hip ArthroplastyCOMPLETEDPHASE42006-042008-022008-02
NCT00365339Drug Interaction Study With Famotidine, Atazanavir, and Atazanavir/Ritonavir/TenofovirCOMPLETEDPHASE12006-042006-062006-06
NCT00289640Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV MelanomaCOMPLETEDPHASE22006-042007-072007-07
NCT00300027Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal (GI) MalignanciesTERMINATEDPHASE12006-042006-12
NCT00326131A Phase I Study of a Single Dose of Radio-labeled BMS-275183 in Patients With Advanced CancerTERMINATEDPHASE12006-042007-03
NCT00306202Study of Dasatinib in Children and Adolescents With Relapsed or Refractory LeukemiaCOMPLETEDPHASE12006-03-312019-05-222011-05-31
NCT00298467MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell LymphomaWITHDRAWNPHASE22006-02
NCT00298987A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib MesylateCOMPLETEDPHASE22006-022007-062007-06
NCT02262520Phase 1 Drug Interaction Study of the Effect of Apixaban on the PK of Digoxin in Healthy SubjectsCOMPLETEDPHASE12006-012006-032006-03
NCT00323882Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate CancerCOMPLETEDPHASE1, PHASE22006-012013-072009-09
NCT00254293Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)COMPLETEDPHASE1, PHASE22006-012012-072007-05
NCT00803556Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab TherapyCOMPLETEDPHASE12006-012009-082009-08
NCT01030718Rollover Study of BMS-354825 in Patients With CML and Ph+ALLCOMPLETEDPHASE1, PHASE22006-012009-062009-06
NCT00295282A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative ColitisCOMPLETEDPHASE12006-012008-012008-01
NCT00207051BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal MalignanciesCOMPLETEDPHASE12006-012008-122008-12
NCT00135408A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral BudesonideCOMPLETEDPHASE22005-122007-072007-07
NCT00773344Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed HerceptinCOMPLETEDPHASE1, PHASE22005-122009-082009-05
NCT00309023Study of BMS-663513 in Patients With Advanced CancerTERMINATEDPHASE1, PHASE22005-122009-092008-12
NCT00978731Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic StudyCOMPLETEDPHASE12005-122008-092008-09
NCT00284804A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's DiseaseCOMPLETEDPHASE22005-112009-102008-05
NCT00272779BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose TruvadaCOMPLETEDPHASE32005-112008-102007-06
NCT00110422Irbesartan in the Treatment of Hypertensive Patients With Metabolic SyndromeCOMPLETEDPHASE42005-112007-022007-02
NCT00207142Induction-Maintenance With Atazanavir in HIV Naïve Patients (The INDUMA Study)COMPLETEDPHASE42005-112008-012007-08
NCT00135421Study of BMS-562086 in the Treatment of Outpatients With Major Depressive DisorderCOMPLETEDPHASE1, PHASE22005-112007-102007-10
NCT00261365Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)COMPLETEDPHASE1, PHASE22005-112007-102007-10
NCT00162292Multiple Ascending Dose Study of BMS-582949 in Patients With Stable Rheumatoid Arthritis on the Methotrexate BackgroundCOMPLETEDPHASE12005-112007-102007-10
NCT00252005Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT StudyCOMPLETEDPHASE22005-112007-022007-02
NCT00388557Effect of Ketoconazole on the Pharmacokinetics of VinflunineCOMPLETEDPHASE12005-102007-09
NCT00855764Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck CancerCOMPLETEDPHASE22005-102006-102006-10
NCT00162149ATV/Ritonavir Nevirapine Interaction (USPAC)COMPLETEDPHASE12005-102006-072006-07
NCT00119678Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With PrednisoneCOMPLETEDPHASE22005-092008-112008-11
NCT00162214Study of Dasatinib in Patients With Advanced Solid TumorsTERMINATEDPHASE12005-082007-032007-03
NCT00106808Study of Muraglitazar Versus Pioglitazone in Type 2 DiabetesCOMPLETEDPHASE32005-082006-082006-08
NCT00112580MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By SurgeryCOMPLETEDPHASE22005-07-312009-06-302009-06-30
NCT00123474Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CMLCOMPLETEDPHASE32005-072014-072006-09
NCT00337454Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in JapanCOMPLETEDPHASE1, PHASE22005-072007-032007-03
NCT00122382Remission and Joint Damage Progression in Early Rheumatoid ArthritisCOMPLETEDPHASE32005-072009-022008-02
NCT00135356Study of Reyataz in HIV-infected Patients With Lipodystrophy SyndromeCOMPLETEDPHASE42005-072008-062007-07
NCT00315237Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial TractCOMPLETEDPHASE32005-072008-012008-01
NCT00971945Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast CancerCOMPLETEDPHASE22005-06-302008-03-312008-03-31
NCT00312754A Phase IV Study of BMS-232632 in HIV+ Patients With Metabolic SyndromeTERMINATEDPHASE42005-062007-042007-04
NCT00123487Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CMLCOMPLETEDPHASE32005-062013-062006-11
NCT00337532A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck CancerCOMPLETEDPHASE2, PHASE32005-052007-062007-06
NCT00198289Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their LungsCOMPLETEDPHASE22005-042006-06
NCT00124982Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF TherapyCOMPLETEDPHASE32005-042009-082009-08
NCT00162253Study of BMS-587101 in Patients With Moderate to Severe PsoriasisTERMINATEDPHASE22005-042006-06
NCT00256750Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)COMPLETEDPHASE32005-032015-042008-06
NCT00114777Study of Belatacept in Subjects Who Are Undergoing a Renal TransplantCOMPLETEDPHASE32005-022014-092008-05
NCT00095147Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid ArthritisCOMPLETEDPHASE32005-022009-072009-07
NCT00124449Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult PatientsCOMPLETEDPHASE22005-022008-042007-05
NCT00101660Study of BMS-354825 (Dasatinib) in Patients With Chronic Myeloid Leukemia Who Are Either Resistant or Intolerant to ImatinibCOMPLETEDPHASE22005-022008-042006-09
NCT00103844Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid LeukemiaCOMPLETEDPHASE22005-022008-032006-08
NCT00101595Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaCOMPLETEDPHASE22005-012007-122007-12
NCT00162448A Phase I Study to Assess the Electrophysiologic Effects of BMS-394136 on the Atrium and Ventricle in Patients With Dual-Chamber Pacemakers or DefibrillatorsCOMPLETEDPHASE12005-01
NCT00101608Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the UrotheliumCOMPLETEDPHASE22005-012007-042007-04
NCT00101647Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid LeukemiaCOMPLETEDPHASE22004-122008-032006-08
NCT00096785Comparative Trial of Entecavir Versus Adefovir in the Treatment of Chronic Hepatitis B InfectionCOMPLETEDPHASE32004-122008-042006-01
NCT00101816Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib MesylateCOMPLETEDPHASE22004-122008-032006-08
NCT00104130Study of KOS-862 (Epothilone D) in Metastatic Prostate CancerTERMINATEDPHASE22004-122005-02
NCT00162097Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic ImpairmentCOMPLETEDPHASE12004-112008-032008-03
NCT00097357BMS-562247 in Subjects Undergoing Elective Total Knee Replacement SurgeryCOMPLETEDPHASE2, PHASE32004-102005-122005-12
NCT00095550Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate HypertensionCOMPLETEDPHASE32004-102005-062005-06
NCT00207025A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced MalignanciesTERMINATEDPHASE12004-102007-02
NCT00095758A Study of Adjunctive Aripiprazole in Patients With Major Depressive DisorderCOMPLETEDPHASE32004-092006-122006-12
NCT00094653MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic MelanomaCOMPLETEDPHASE32004-092009-102009-08
NCT00135434Effect of HIV Protease Inhibitor Drugs on Glucose and Insulin MetabolismCOMPLETEDPHASE12004-092005-062005-06
NCT00207103MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid TumorsCOMPLETEDPHASE12004-092008-092007-10
NCT00095290Irbesartan Versus Placebo in Combination With Ramipril for Treatment of AlbuminuriaCOMPLETEDPHASE42004-092005-112005-11
NCT00095394Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe HypertensionCOMPLETEDPHASE32004-092005-052005-05
NCT00279734Vaccination Study of Abatacept (BMS-188667) for Normal Healthy VolunteersCOMPLETEDPHASE12004-082005-012005-01
NCT00099606Phase I (PH I) Mad Refractory Solid Tumor StudyCOMPLETEDPHASE12004-072007-072007-07
NCT00095823A Study of Adjunctive Aripiprazole in Patients With Major Depressive DisorderCOMPLETEDPHASE32004-062006-082006-08
NCT00084253Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive PatientsCOMPLETEDPHASE42004-062006-08
NCT00084656Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV MelanomaCOMPLETEDPHASE22004-05-312009-10-312009-10-31
NCT00113191Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature InfantsCOMPLETEDNA2004-052006-062006-06
NCT00975091Continue Entecavir Rollover From ChinaCOMPLETEDPHASE32004-052007-082007-08
NCT00207012MAD Refractory: Solid Tumor QD w/o BreakCOMPLETEDPHASE12004-052006-02
NCT00135395A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART RegimenCOMPLETEDPHASE32004-052006-022006-02
NCT00094991Mechanism of Action and Efficacy of Muraglitazar in Type 2 DiabetesCOMPLETEDPHASE32004-052006-052006-05
NCT00207168To Assess Compliance With a Once-daily Regimen of Lamivudine, Efavirenz and DidanosineCOMPLETEDPHASE42004-042006-122006-12
NCT00135343A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing RegimenCOMPLETEDPHASE32004-042005-102005-10
NCT00095537BMS-599626 in Patients With Advanced Solid MalignanciesCOMPLETEDPHASE12004-032006-05
NCT00002207A Comparison of Two Dose Levels of Didanosine Used in Combination With Stavudine in HIV-Infected PatientsCOMPLETEDNA2004-022004-022004-02
NCT00095030Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin AloneCOMPLETEDPHASE32004-022006-032006-03
NCT01024101Early Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Advanced or Recurrent Head and Neck CancerCOMPLETEDPHASE22004-012005-122005-12
NCT00990912A Study to Document Long-Term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects With Refractory Solid Tumors (Rollover Study -001, -002)COMPLETEDPHASE1, PHASE22004-012005-112005-11
NCT00120393Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/RitonavirCOMPLETEDPHASE32004-012006-052006-05
NCT00095173BMS-188667 in Children and Adolescents With Juvenile Rheumatoid ArthritisCOMPLETEDPHASE32003-122011-112006-06
NCT01037062An Open-Label Rollover Study of Entecavir (BMS-200475) in Adults With Chronic Hepatitis B InfectionCOMPLETEDPHASE22003-122006-122006-12
NCT00080509Effectiveness of KOS-862 in the Treatment of Lung CancerTERMINATEDPHASE22003-122004-11
NCT00103701BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic LeukemiaCOMPLETEDPHASE12003-112006-032006-03
NCT00162201An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF TherapyCOMPLETEDPHASE12003-102005-042005-04
NCT00240370A Study to Evaluate Combining Metformin With Muraglitazar or Pioglitazone in Type 2 DiabeticsCOMPLETEDPHASE32003-102005-03
NCT00065507Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic DecompensationCOMPLETEDPHASE32003-082013-052008-10
NCT01022801A Phase II Dose Response Study in Japan in Chronic Hepatitis BCOMPLETEDPHASE22003-082005-032005-03
NCT00729950Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant MelanomaCOMPLETEDPHASE12003-072007-062005-10
NCT00162175PPAR-COMBO With SulfonylureaCOMPLETEDPHASE32003-072005-112005-11
NCT00162240PPAR - Combination With MetforminCOMPLETEDPHASE32003-062004-05
NCT00246987A Trial to Evaluate BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic ControlCOMPLETEDPHASE32003-062004-04
NCT00083278Study of MDX-010 in Stage IV Breast CancerCOMPLETEDPHASE22003-052006-02
NCT03407105A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV)COMPLETEDPHASE12003-04-212006-02-212006-02-21
NCT00057473A Phase II Study of Carboplatin Plus Irinotecan Versus Irinotecan in Children With Refractory Solid TumorsCOMPLETEDPHASE22003-022004-022004-02
NCT01020565A Study in Japan of the Safety and Antiviral Activity With Chronic Hepatitis B InfectionCOMPLETEDPHASE22003-022005-022005-02
NCT00048581Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.COMPLETEDPHASE32002-122009-092009-09
NCT00048932A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid ArthritisCOMPLETEDPHASE32002-122009-102009-10
NCT00048568A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to MethotrexateCOMPLETEDPHASE32002-122009-102009-10
NCT00529178Pravastatin Efficacy and Safety Trial in Hypercholesterolemic Patients With Chronic Liver DiseaseCOMPLETEDPHASE42002-122005-032005-03
NCT01024062Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC)COMPLETEDPHASE22002-122005-032005-03
NCT01037166Study in Japan of the Safety And Antiviral Activity in Adults With Chronic Hepatitis B Current Lamivudine TherapyCOMPLETEDPHASE22002-122005-022005-02
NCT00067782A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral TherapyCOMPLETEDPHASE32002-122005-032005-03
NCT00050596Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate CancerCOMPLETEDPHASE22002-112004-112004-11
NCT01003990Roll-Over Protocol To Provide Atv And/Or Truvada For Extended AccessCOMPLETEDPHASE32002-102016-022016-02
NCT00050102Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic MelanomaCOMPLETEDPHASE22002-102004-022004-02
NCT01023204Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast CancerCOMPLETEDPHASE22002-102005-072005-07
NCT00277199Comparability DE vs CD-CHO1COMPLETEDPHASE12002-092002-122002-12
NCT00135369Switching HIV-1 Infected Subjects From a Highly Active Anti-Retroviral Treatment (HAART) Regimen Dosed Twice Daily or More Frequently to a Once-Daily RegimenCOMPLETEDPHASE32002-092005-072005-07
NCT00051038Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected PatientsCOMPLETEDPHASE2, PHASE32002-092005-102005-10
NCT00095238Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)COMPLETEDPHASE32002-062008-072008-07
NCT00135382Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based RegimenCOMPLETEDPHASE32002-062005-102005-10
NCT00240383Dose Ranging Study With LT, Monotherapy, PPARCOMPLETEDPHASE2, PHASE32002-052006-062006-06
NCT00245388Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in Subjects With Mixed DyslipidemiaCOMPLETEDPHASE2, PHASE32002-042002-07
NCT00116116DART II - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral TherapyCOMPLETEDPHASE42002-032005-062005-06
NCT00116415DART I - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral TherapyCOMPLETEDNA2002-032004-112004-11
NCT00035568A Research Study to Assess the Mechanism By Which Glucovance, Metformin, and Glyburide Work To Control Glucose Levels In Patients With Type 2 DiabetesCOMPLETEDPHASE42002-022003-062003-06
NCT00036608A Phase III Study of Entecavir vs Lamivudine in Chronic Hepatitis B Subjects With Incomplete Response to LamivudineCOMPLETEDPHASE32002-012005-022005-02
NCT00035542A Research Study to Determine the Safety and Efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents With Type 2 Diabetes.COMPLETEDPHASE32001-122003-102003-10
NCT00035633A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Positive for Hepatitis B E AntigenCOMPLETEDPHASE32001-122005-022005-02
NCT00035529A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple SclerosisTERMINATEDPHASE22001-112003-122003-12
NCT00035932Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIVCOMPLETEDPHASE32001-112009-032003-07
NCT00035789A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e AntigenCOMPLETEDPHASE32001-112005-052005-05
NCT00030173A Trial to Evaluate Epothilone D in Patients With Advanced Solid TumorsCOMPLETEDPHASE12001-102003-06
NCT00028067A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease InhibitorTERMINATEDPHASE32001-082002-042002-04
NCT00024284Carboplatin and Irinotecan in Treating Children With Refractory Solid TumorsCOMPLETEDPHASE12001-062003-122003-12
NCT00035555Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted KidneyCOMPLETEDPHASE22001-032012-072004-01
NCT00017043BMS-247550 in Treating Patients With Metastatic Stomach Cancer Previously Treated With ChemotherapyCOMPLETEDPHASE22001-022003-012003-01
NCT00013897A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-LamivudineCOMPLETEDPHASE32001-022003-042003-04
NCT00028301Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)COMPLETEDPHASE32001-022003-092003-09
NCT01438424Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir TrialsCOMPLETEDPHASE22001-012011-042009-12
NCT00116298Rollover Study for Zerit (Stavudine) ER Studies (-096, -099)COMPLETEDPHASE32001-012005-012005-01
NCT00382460Pravastatin or Atorvastatin Evaluation and Infection Therapy (TIMI22)COMPLETEDPHASE42000-112003-122003-12
NCT00162266Abatacept With Methotrexate- Phase IIBCOMPLETEDPHASE22000-102009-092009-09
NCT00162279The Study of Abatacept in Combination With EtanerceptCOMPLETEDPHASE22000-102007-022007-02
NCT00035152Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung CancerCOMPLETEDPHASE32000-062004-12
NCT00005918Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected PatientsCOMPLETEDPHASE32000-062002-042002-04
NCT00437437A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)COMPLETEDPHASE12000-052013-022008-05
NCT00004584Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous TreatmentCOMPLETEDPHASE21999-122002-012002-01
NCT00002429Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug RegimenCOMPLETEDPHASE31999-072001-012001-01
NCT00002224Comparison of Two Anti-HIV Regimens That Include One of Two Forms of Didanosine (ddI)COMPLETEDPHASE31999-031999-031999-03
NCT00002360A Study Comparing Two Forms of Didanosine in HIV-infected PatientsCOMPLETEDPHASE11999-031999-031999-03
NCT00002240Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV DrugsCOMPLETEDPHASE21999-032001-122001-12
NCT00002411A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated With Anti-HIV DrugsCOMPLETEDNA1998-031999-091999-09
NCT00002246A Study to Evaluate the Use of Stavudine (d4T) to Treat AIDS Dementia ComplexCOMPLETEDPHASE31997-101999-031999-03
NCT00002176A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV InfectionCOMPLETEDNA1997-052000-032000-03
NCT00002177A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Recent HIV InfectionCOMPLETEDNA1997-052000-032000-03
NCT00287547Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis VulgarisCOMPLETEDPHASE21997-031998-011998-01
NCT00002371The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken ZidovudineCOMPLETEDPHASE31996-061997-121997-12
NCT00277225A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis VulgarisCOMPLETEDPHASE11995-111996-061996-06
NCT00306878Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis VulgarisCOMPLETEDPHASE11995-081997-051997-05
NCT00002349A Pilot Study to Compare the Antiviral and Immunologic Effects of Stavudine ( d4T ) Versus Placebo in Subjects With Evidence of Recent HIV Infection.COMPLETEDNA1995-011999-051999-05
NCT00279760Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid ArthritisCOMPLETEDPHASE1, PHASE22002-03
NCT00198302Clinical Trial Comparing Safety and Pharmacokinetics of Standard Antibiotic Therapy, Plus Aurexis® or Placebo, for Treatment of Staphylococcus Aureus Bacteremia (SAB)COMPLETEDPHASE22005-02
NCT00002035Double-Blind Comparison of the Efficacy of Continued Zidovudine Versus 2',3'-Dideoxyinosine (ddI) (BMY-40900) for the Treatment of Patients With AIDS or AIDS-Related Complex and Increasing Symptomatology Despite Treatment With ZidovudineCOMPLETEDNA1992-04
NCT00002280A Study of ddI in Children With AIDS Who Have Not Had Success With ZidovudineCOMPLETEDNA1994-11
NCT00002307A Comparison of Zidovudine (AZT) and Stavudine in HIV-Infected PatientsCOMPLETEDNA1994-12
NCT00002308A Study of Stavudine in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV DrugsCOMPLETEDNA1991-11
NCT00103831Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung CancerCOMPLETEDPHASE1, PHASE22005-05
NCT00002420The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease InhibitorsTERMINATEDPHASE2
NCT00002274A Study of ddI in Patients With AIDS Who Become Sicker While Taking ZidovudineCOMPLETEDNA
NCT00002041Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised PatientsCOMPLETEDNA
NCT00002300A Study of Different Doses of Megestrol Acetate in Patients With AIDS Who Have Anorexia and MalnutritionCOMPLETEDPHASE2
NCT00002345The Safety and Effectiveness of Megace in HIV-Infected WomenCOMPLETEDPHASE4
NCT00002293A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related SyndromesCOMPLETEDNA
NCT00002067A Study Comparing Megestrol Acetate at 800 mg/Day, and Placebo in AIDS Patients With Anorexia and CachexiaCOMPLETEDPHASE3
NCT00002057Nystatin Pastilles for the Prevention of Oral Candidiasis in Patients With AIDS or ARCCOMPLETEDNA
NCT00002358A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZVCOMPLETEDPHASE3
NCT00002168A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected PatientsCOMPLETEDNA
NCT00002369A Comparison of Epivir Plus Crixivan Combined With Zerit or Retrovir in HIV-Infected Patients Who Have Never Taken Anti-HIV DrugsCOMPLETEDNA
NCT00002352A Study of Lobucavir in Patients With AIDSCOMPLETEDNA
NCT00002261A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated VolunteersCOMPLETEDPHASE1
NCT00099879Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung CancerTERMINATEDPHASE22006-03
NCT00036621A Randomized, Placebo-Controlled Trial of BMS-275291 Given Daily for 12 Months to Women With Stage 1c-IIIA Breast Cancer Receiving Adjuvant Chemotherapy and/or Hormonal TherapyTERMINATEDPHASE22002-09
NCT00002028A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir)COMPLETEDNA
NCT00002234Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected PatientsCOMPLETEDPHASE2
NCT00002418The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease InhibitorsTERMINATEDPHASE2